var title_f24_7_24688="Bucket test to find subjective visual vertical";
var content_f24_7_24688=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F66460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F66460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemispheric dome and bucket method of subjective visual vertical testing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 186px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The bucket method for determining monocular and binocular visual vertical: patients sit upright looking into a translucent plastic bucket so that the bucket rims prevent any gravitational orientation clues. On the bottom inside the bucket there is a dark, straight, diametric line. On the bottom outside there is a perpendicular that originates from the center of a quadrant divided into degrees with the zero line corresponding to the true vertical. For measurement, the examiner rotates the bucket clockwise or counterclockwise to an end position and then slowly rotates it back toward the zero degree position. Patients indicate the position where they estimate the inside bottom line to be truly vertical by signaling stop. The examiner reads off the degrees on the outside scale. A total of 10 repetitions&nbsp;are performed. An eye patch&nbsp;is used for monocular testing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zwergal A, Rettinger N, Frenzel C, et al. A bucket of static vestibular function. Neurology 2009; 72:1689. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_7_24688=[""].join("\n");
var outline_f24_7_24688=null;
var title_f24_7_24689="Central retinal vein occ";
var content_f24_7_24689=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Central retinal vein occlusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 383px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intraretinal hemorrhages in all four quadrants on funduscopic examination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_7_24689=[""].join("\n");
var outline_f24_7_24689=null;
var title_f24_7_24690="Cool temperature hemodialysis: Hemodynamic effects";
var content_f24_7_24690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"19\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cool temperature hemodialysis: Hemodynamic effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/7/24690/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24690/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/7/24690/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24690/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/7/24690/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24690/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/7/24690/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     OVERVIEW AND EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of cooler temperature dialysate (35&ordm;C versus the traditional 37&ordm;C) has gained popularity in the treatment of episodic hypotension during hemodialysis among patients undergoing chronic hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two different ways of reducing dialysate fluid temperature:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Empiric fixed reductions of dialysate temperature",
"     </li>",
"     <li>",
"      Isothermic dialysis, a technique in which body temperature remains constant via the use of a biofeedback temperature-controlled device",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although several early reports suggested improved hemodynamic tolerance with cool temperature dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24690/abstract/1-3\">",
"     1-3",
"    </a>",
"    ], confirmation by long-term trials has been attained [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24690/abstract/4-13\">",
"     4-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of cool temperature dialysis was best assessed in a 2006 systematic review of 22 studies that evaluated 408 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24690/abstract/14\">",
"     14",
"    </a>",
"    ]; 16 and 6 studies used empiric fixed temperature reduction and isothermic techniques, respectively. All studies employed a cross-over design.",
"   </p>",
"   <p>",
"    Benefits with cool temperature dialysis included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Markedly fewer episodes of intradialytic hypotension (7.1 times less frequent, 95% CI of 5.3 to 8.9).",
"     </li>",
"     <li>",
"      Higher post-dialysis mean arterial pressure (11.3 mmHg, 95% CI of 7.7 to 15.0 mmHg).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cool temperature dialysis is able to produce more stable hemodynamics without a reduction in urea clearance. Both urea recovery and the postdialysis urea rebound are similar to those seen at 37&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24690/abstract/4,9\">",
"     4,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cool temperature dialysis lowers the body temperature by about 1&ordm;C. This change is generally well-tolerated, although some patients develop unacceptable side effects such as chilling or cramping. In the systematic review previously mentioned, it was concluded that the description of adverse effects was inadequate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24690/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines and 2007 European best practice guidelines in hemodialysis recommend the use of cool dialysate temperature dialysis in patients with frequent episodes of intradialytic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24690/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Specifically, the European guidelines recommend cool temperature dialysis (35 to 36&ordm;C) or isothermic treatments by blood temperature controlled feedback [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24690/abstract/16\">",
"     16",
"    </a>",
"    ]. Dialysate temperature should be gradually reduced by increments of 0.5&ordm;C until symptoms are resolved, but temperatures below 35&ordm;C should not be used.",
"   </p>",
"   <p>",
"    A discussion of hemodynamic instability in dialysis including our recommended approach, the use of cool temperature hemodialysis, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise manner by which cool temperature dialysis improves vascular stability is not completely understood. Both increased systemic vascular resistance and enhanced cardiac contractility have been observed, changes that may be mediated at least in part by cold-induced activation of the sympathetic nervous system and decreased silent ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24690/abstract/6,14,17-21\">",
"     6,14,17-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29672652\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of cooler temperature dialysate is an effective way to treat episodic hypotension during hemodialysis and is recommended by several best practice guidelines. Cooler temperature dialysis may be done using empiric fixed reductions of dialysate temperature or by targeting a constant body temperature using a biofeedback temperature-controlled device. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview and efficacy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cool temperature dialysis lowers the body temperature by about 1&ordm;C. This change is generally well-tolerated, although some patients develop chilling or cramping. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview and efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism by which cool temperature dialysis improves vascular stability is not completely understood and may include increases in systemic vascular resistance and cardiac contractility. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/1\">",
"      Maggiore Q, Pizzarelli F, Zoccali C, et al. Effect of extracorporeal blood cooling on dialytic arterial hypotension. Proc Eur Dial Transplant Assoc 1981; 18:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/2\">",
"      Lindholm T, Thysell H, Yamamoto Y, et al. Temperature and vascular stability in hemodialysis. Nephron 1985; 39:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/3\">",
"      Sherman RA, Rubin MP, Cody RP, Eisinger RP. Amelioration of hemodialysis-associated hypotension by the use of cool dialysate. Am J Kidney Dis 1985; 5:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/4\">",
"      Quereda C, Orofino L, Marcen R, et al. Influence of dialysate and membrane biocompatibility on hemodynamic stability in hemodialysis. Int J Artif Organs 1988; 11:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/5\">",
"      Orofino L, Marc&eacute;n R, Quereda C, et al. Epidemiology of symptomatic hypotension in hemodialysis: is cool dialysate beneficial for all patients? Am J Nephrol 1990; 10:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/6\">",
"      Jost CM, Agarwal R, Khair-el-Din T, et al. Effects of cooler temperature dialysate on hemodynamic stability in \"problem\" dialysis patients. Kidney Int 1993; 44:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/7\">",
"      Schneditz D, Martin K, Kr&auml;mer M, et al. Effect of controlled extracorporeal blood cooling on ultrafiltration-induced blood volume changes during hemodialysis. J Am Soc Nephrol 1997; 8:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/8\">",
"      Cruz DN, Mahnensmith RL, Brickel HM, Perazella MA. Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension. Am J Kidney Dis 1999; 33:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/9\">",
"      Yu AW, Ing TS, Zabaneh RI, Daugirdas JT. Effect of dialysate temperature on central hemodynamics and urea kinetics. Kidney Int 1995; 48:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/10\">",
"      Maggiore Q, Pizzarelli F, Santoro A, et al. The effects of control of thermal balance on vascular stability in hemodialysis patients: results of the European randomized clinical trial. Am J Kidney Dis 2002; 40:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/11\">",
"      Schneditz D, Ronco C, Levin N. Temperature control by the blood temperature monitor. Semin Dial 2003; 16:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/12\">",
"      P&eacute;rgola PE, Habiba NM, Johnson JM. Body temperature regulation during hemodialysis in long-term patients: is it time to change dialysate temperature prescription? Am J Kidney Dis 2004; 44:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/13\">",
"      Pizzarelli F. From cold dialysis to isothermic dialysis: a twenty-five year voyage. Nephrol Dial Transplant 2007; 22:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/14\">",
"      Selby NM, McIntyre CW. A systematic review of the clinical effects of reducing dialysate fluid temperature. Nephrol Dial Transplant 2006; 21:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/15\">",
"      K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/16\">",
"      Tattersall, J, Martin-Malo, A, Pedrini, L, et al. European best practice guidelines on haemodialysis. Nephrol Dial Transplant 2007; 22(Suppl 2):ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/17\">",
"      Levy FL, Grayburn PA, Foulks CJ, et al. Improved left ventricular contractility with cool temperature hemodialysis. Kidney Int 1992; 41:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/18\">",
"      Coli U, Landini S, Lucatello S, et al. Cold as cardiovascular stabilizing factor in hemodialysis: hemodynamic evaluation. Trans Am Soc Artif Intern Organs 1983; 29:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/19\">",
"      Mahida BH, Dumler F, Zasuwa G, et al. Effect of cooled dialysate on serum catecholamines and blood pressure stability. Trans Am Soc Artif Intern Organs 1983; 29:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/20\">",
"      Selby NM, Burton JO, Chesterton LJ, McIntyre CW. Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate. Clin J Am Soc Nephrol 2006; 1:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24690/abstract/21\">",
"      van der Sande FM, Wystrychowski G, Kooman JP, et al. Control of core temperature and blood pressure stability during hemodialysis. Clin J Am Soc Nephrol 2009; 4:93.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1949 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-115.25.216.6-4DBC96805C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_7_24690=[""].join("\n");
var outline_f24_7_24690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29672652\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      OVERVIEW AND EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29672652\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overvie",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_7_24691="Finger web intertrigo";
var content_f24_7_24691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candida intertrigo of the finger web",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Also called \"erosio interdigitalis blastomycetica,\" this eczematous process presented in a bartender whose hands were constantly wet. In the acute phase, this typically has a more macerated appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Habif, T. Clinical Dermatology: A Color Guide to Diagnosis and Therapy, 4th ed, Mosby, New York 2004. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_7_24691=[""].join("\n");
var outline_f24_7_24691=null;
var title_f24_7_24692="Trimethobenzamide: Pediatric drug information";
var content_f24_7_24692=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trimethobenzamide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?3/63/4085?source=see_link\">",
"    see \"Trimethobenzamide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/2/29732?source=see_link\">",
"    see \"Trimethobenzamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F231401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tigan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tigan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/63/4085?source=see_link\">",
"      see \"Trimethobenzamide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 15-20 mg/kg/day (400-500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day) divided into 3-4 doses;",
"     <b>",
"      or as an alternative",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;13.6 kg: 100 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     13.6-40 kg: 100-200 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;40 kg: 300 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 300 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 200 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Postoperative nausea and vomiting (PONV): I.M.: 200 mg, followed 1 hour later by a second 200 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;70 mL/minute: Consider dosage reduction or increasing dosing interval (specific adjustment guidelines are not provided in the manufacturer&rsquo;s labeling)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F231381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tigan&reg;: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 100 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tigan&reg;: 100 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 100 mg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tigan&reg;: 100 mg/mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F231368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May administer without regard to food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.M. use only by deep injection into upper outer quadrant of gluteal region;",
"     <b>",
"      not",
"     </b>",
"     for I.V. use",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F6839846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Glycopyrrolate, hydromorphone, midazolam, nalbuphine, pentazocine.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Heparin, hydrocortisone sodium succinate, potassium chloride, vitamin B complex with C.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2523447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of postoperative nausea and vomiting; treatment of nausea and vomiting associated with gastroenteritis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F231426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tigan&reg; may be confused with Tiazac&reg;, Ticlid",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Trimethobenzamide may be confused with metoclopramide, trimethoprim",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F231424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension (I.V. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Coma, depression, disorientation, dizziness, drowsiness, EPS, headache, Parkinson-like symptoms, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Allergic-type skin reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Blood dyscrasias",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site burning, pain, redness, stinging, or swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps, opisthotonos",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to trimethobenzamide or any component; injection is contraindicated in children",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Risk of adverse effects (eg, EPS, seizure) may be increased in patients with acute febrile illness, dehydration, electrolyte imbalance, encephalitides, or gastroenteritis; use with caution. Allergic-type skin reactions have been reported with use; discontinue with signs of sensitization. Trimethobenzamide clearance is predominantly renal; consider dosage reductions in patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6893429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use cautiously in infants and children; antiemetics are not recommended for uncomplicated vomiting in children; limit antiemetic use to prolonged vomiting of known etiology;  may mask emesis due to Reye's syndrome, may mimic CNS effects of Reye's syndrome in patients with emesis of other etiologies, and may cause extrapyramidal symptoms (EPS) which may be confused with CNS symptoms of primary disease responsible for emesis. May produce drowsiness and concomitant use with alcohol may result in an adverse interaction.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6200344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1628164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Safety and efficacy have not been established in pregnant patients. Trimethobenzamide has been used to treat nausea and vomiting of pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acts centrally to inhibit stimulation of the medullary chemoreceptor trigger zone",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1062768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 10-40 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 15-35 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 2-3 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via oxidation, forms metabolite trimethobenzamide N-oxide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral dose is 100% of I.M. dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 7-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 30% to 50% excreted unchanged in urine in 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1062761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/2/29732?source=see_link\">",
"      see \"Trimethobenzamide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1062771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Less effective than phenothiazines but may be associated with fewer side effects",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Leung AK and Robson WL, \"Acute Gastroenteritis in Children: Role of Anti-Emetic Medication for Gastroenteritis-Related Vomiting,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2007, 9(3):175-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24692/abstract-text/17523698/pubmed\" id=\"17523698\" target=\"_blank\">",
"        17523698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12864 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-EBA391572F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_7_24692=[""].join("\n");
var outline_f24_7_24692=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231401\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231402\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062762\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062758\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231381\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231368\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062766\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6839846\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2523447\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062765\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231426\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231424\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062770\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062757\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6893429\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300179\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6200344\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1628164\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062756\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062768\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062769\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062761\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062771\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12864\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12864|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/63/4085?source=related_link\">",
"      Trimethobenzamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/2/29732?source=related_link\">",
"      Trimethobenzamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_7_24693="Clinical manifestations of Crohn's disease in children and adolescents";
var content_f24_7_24693=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of Crohn's disease in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/7/24693/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24693/contributors\">",
"     Athos Bousvaros, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24693/contributors\">",
"     Tyler Burpee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24693/contributors\">",
"     Alan Leichtner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/7/24693/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24693/contributors\">",
"     George D Ferry, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24693/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/7/24693/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24693/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/7/24693/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crohn's disease (CD, also known as regional enteritis) is an immune-mediated inflammatory disease that can affect any portion of the intestinal tract from the mouth to the anus. The disease usually is localized, most commonly to the ileum, ileum and cecum, or ileum and entire colon. Gastritis and upper intestinal tract inflammation are present in 30 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=see_link\">",
"     \"Definition, epidemiology, and risk factors in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of CD is approximately 5 to 10 new cases per 100,000",
"    <span class=\"nowrap\">",
"     individuals/year.",
"    </span>",
"    Approximately 20 to 25 percent of these cases are diagnosed in children younger than age 18 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24693/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the exact pathophysiology has not been fully defined, there is both a genetic and environmental component. It is likely that inherited gene mutations may predispose individuals with CD to an inflammatory response directed against intraluminal antigens (including intestinal bacteria, dietary antigens, and environmental antigens such as tobacco smoke). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=see_link\">",
"     \"Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44455?source=see_link\">",
"     \"Genetic factors in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of CD in children and adolescents are reviewed here. The diagnosis of CD, including the differentiation from Ulcerative Colitis, and the management of CD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41722?source=see_link\">",
"     \"Overview of the management of Crohn's disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with CD may present with intestinal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extraintestinal manifestations (",
"    <a class=\"graphic graphic_table graphicRef51513 \" href=\"UTD.htm?19/8/19595\">",
"     table 1",
"    </a>",
"    ). Intestinal manifestations are more common. In one of the largest series of children who were younger than 10 years of age, the most common presenting symptoms were [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24693/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal pain (95 percent)",
"     </li>",
"     <li>",
"      Weight loss (80 percent)",
"     </li>",
"     <li>",
"      Diarrhea (77 percent)",
"     </li>",
"     <li>",
"      Hematochezia (60 percent)",
"     </li>",
"     <li>",
"      Growth failure (30 percent)",
"     </li>",
"     <li>",
"      Extraintestinal manifestations (20 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DISEASE LOCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD in children and adolescents can involve the terminal ileum only (20 to 30 percent), colon only (20 percent), and both ileum and colon (40 to 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24693/abstract/3\">",
"     3",
"    </a>",
"    ]. A small number of children have more diffuse small bowel disease, isolated perianal disease, or severe orofacial disease. Patients may be classified by age, disease location (ileum only, colon only, ileocolon, or upper gastrointestinal tract), and disease behavior (inflammatory, stricturing, or penetrating), as described in the \"Montreal\" classification system [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24693/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NUTRITION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Growth failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth failure is an especially important presenting feature [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24693/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Growth failure can be defined dynamically as a fall in the height percentile of more than 0.3 standard",
"    <span class=\"nowrap\">",
"     deviation/year,",
"    </span>",
"    a growth velocity of less than 5",
"    <span class=\"nowrap\">",
"     cm/year,",
"    </span>",
"    or a decrease in the growth velocity of more than or equal to 2 cm compared with the previous year, during early to mid-puberty. To assess most accurately for growth failure, a child&rsquo;s growth rate should be compared with expected growth rates for age (",
"    <a class=\"graphic graphic_figure graphicRef70382 \" href=\"UTD.htm?6/6/6253\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=see_link\">",
"     \"Diagnostic approach to short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study using these definitions found that approximately 30 percent of children with CD had growth failure compared with 5 to 10 percent of children with ulcerative colitis (UC) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24693/abstract/5\">",
"     5",
"    </a>",
"    ]. In another report, approximately 50 percent of children with untreated CD had short stature or evidence of diminished height velocity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24693/abstract/6\">",
"     6",
"    </a>",
"    ]. The fall-off in height velocity may occur before the onset of symptoms and may be unrecognized by the parents, but it can be detected by plotting a patient's height and weight on the appropriate growth chart. Delayed sexual maturation (pubertal delay) commonly accompanies the growth failure in adolescents.",
"   </p>",
"   <p>",
"    The causes, assessment, and management of growth failure and poor weight gain in children with IBD are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2794?source=see_link\">",
"     \"Growth failure and poor weight gain in children with inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Micronutrient deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of micronutrient deficiencies have been associated with CD. These include deficiencies in vitamins A, D, and E, zinc, and Vitamin B12 (the latter is most common in patients with ileal CD). Vitamin D deficiency appears to be the most common deficiency and may predispose to osteopenia. In general, patients with active disease have a higher prevalence of micronutrient deficiencies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41722?source=see_link&amp;anchor=H32#H32\">",
"     \"Overview of the management of Crohn's disease in children and adolescents\", section on 'Bone mineral density'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=see_link\">",
"     \"Nutrient deficiencies in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ORAL AND PERIANAL LESIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Perianal lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perianal abnormalities are common. In one report, for example, 67 of 230 (29 percent) children and adolescents with CD had significant perianal pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24693/abstract/8\">",
"     8",
"    </a>",
"    ]. Perianal involvement may be mild (consisting of small skin tags or anal fissures) or more severe (abscesses and fistulae). In a series of pediatric patients with CD, 10 percent had perianal fistulas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abscesses at the time of diagnosis, and one third of these had persistent perianal disease for more than one year despite treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24693/abstract/9\">",
"     9",
"    </a>",
"    ]. As many as 5 percent of children develop a highly destructive form of perianal disease which is characterized by recurrent perianal abscesses, fistulae involving the genitalia, and the development of rectal strictures (",
"    <a class=\"graphic graphic_picture graphicRef75104 \" href=\"UTD.htm?34/20/35136\">",
"     picture 1",
"    </a>",
"    ). Such severe disease may be refractory to medical treatment (including corticosteroids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) and may require colonic diversion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24693/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=see_link\">",
"     \"Perianal complications of Crohn's disease\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Oral lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral lesions are common in children with CD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24693/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In a prospective study, 48 of 49 children with suspected IBD who had a final diagnosis of CD were examined by a dentist [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24693/abstract/11\">",
"     11",
"    </a>",
"    ]. Oral manifestations of CD were detected by the dentist in 20 children (42 percent) and included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mucogingivitis (12 patients) (",
"      <a class=\"graphic graphic_picture graphicRef56573 \" href=\"UTD.htm?25/37/26207\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mucosal tags (4 patients) (",
"      <a class=\"graphic graphic_picture graphicRef70350 \" href=\"UTD.htm?6/56/7055\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Deep ulceration (4 patients) (",
"      <a class=\"graphic graphic_picture graphicRef54825 \" href=\"UTD.htm?16/47/17151\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cobblestoning (3 patients) (",
"      <a class=\"graphic graphic_picture graphicRef71733 \" href=\"UTD.htm?8/28/8655\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lip swelling (3 patients) (",
"      <a class=\"graphic graphic_picture graphicRef58499 \" href=\"UTD.htm?34/32/35342\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pyostomatitis vegetans (1 patient)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Isolated orofacial and perianal findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated orofacial and perianal inflammation can occur in the absence of bowel disease or may precede the development of bowel disease by several years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24693/abstract/13\">",
"     13",
"    </a>",
"    ]. In these patients, a biopsy of the inflamed lips, buccal mucosa, or perianal skin tags may demonstrate granulomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EXTRAINTESTINAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraintestinal conditions associated with CD may be identified on history or physical examination. These may involve the skin, joints, liver, eye, and (rarely) respiratory system (",
"    <a class=\"graphic graphic_table graphicRef81867 \" href=\"UTD.htm?27/32/28173\">",
"     table 2",
"    </a>",
"    ). These disorders appear idiosyncratically in some patients and not others, but are more often associated with colonic disease; they do not consistently correlate with the degree of intestinal inflammation. These are discussed in detail in a separate topic review (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link&amp;anchor=H1351752#H1351752\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\", section on 'Extraintestinal manifestations'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CD involves five steps. The first two typically are performed by the general pediatrician, while the last three are performed by the pediatric gastroenterologist.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical suspicion of the illness based upon history, examination and screening laboratory data",
"     </li>",
"     <li>",
"      Exclusion of other illnesses that have a similar presentation",
"     </li>",
"     <li>",
"      Differentiation between CD and UC",
"     </li>",
"     <li>",
"      Localization of the region of the disease",
"     </li>",
"     <li>",
"      Identification of extraintestinal manifestations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These steps are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef77827 \" href=\"UTD.htm?11/2/11309\">",
"     table 3",
"    </a>",
"    ) and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8070511\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with CD may present with intestinal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      extraintestinal manifestations (",
"      <a class=\"graphic graphic_table graphicRef51513 \" href=\"UTD.htm?19/8/19595\">",
"       table 1",
"      </a>",
"      ). The most common intestinal manifestations are abdominal pain weight loss, diarrhea, hematochezia, and growth failure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Extraintestinal manifestations of CD may involve the skin, joints, liver, eye, and respiratory system (",
"      <a class=\"graphic graphic_table graphicRef81867 \" href=\"UTD.htm?27/32/28173\">",
"       table 2",
"      </a>",
"      ). These disorders appear idiosyncratically in some patients and not others, but are more often associated with colonic disease; they do not consistently correlate with the degree of intestinal inflammation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Extraintestinal manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Growth failure is present in about 30 percent of children and adolescents with Crohn&rsquo;s disease, and is caused by a combination of anorexia and increased energy needs, related to inflammation. It is heralded by diminishing height velocity, and is best assessed by serial measurements of height, compared with previous height velocity and expected height velocity for age (",
"      <a class=\"graphic graphic_figure graphicRef70382 \" href=\"UTD.htm?6/6/6253\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Growth failure'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2794?source=see_link\">",
"       \"Growth failure and poor weight gain in children with inflammatory bowel disease\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Significant perianal disease, including perianal fistulae or abscesses, occurs in about 30 percent of children and adolescents with Crohn&rsquo;s disease. A highly destructive form of perianal disease occurs in about 5 percent of patients. More minor manifestations of perianal disease include anal fissures and skin tags. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Perianal lesions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=see_link\">",
"       \"Perianal complications of Crohn's disease\"",
"      </a>",
"      .) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Oral lesions occur in up to 40 percent of children with Crohn&rsquo;s disease, and may include mucogingivitis, aphthous ulcers, or swelling. Occasionally, oral and perianal disease occurs in the absence of significant intestinal disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Oral lesions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Isolated orofacial and perianal findings'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Griffiths AM, Hugot JP. Crohn Disease. In: Pediatric Gastrointestinal Disease: Pathopsychology, Diagnosis, Management, 4th, Walker WA, Goulet O, Kleinman RE, et al (Eds), BC Decker, Ontario 2004. p.789.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24693/abstract/2\">",
"      Gryboski JD. Crohn's disease in children 10 years old and younger: comparison with ulcerative colitis. J Pediatr Gastroenterol Nutr 1994; 18:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24693/abstract/3\">",
"      Barton JR, Ferguson A. Clinical features, morbidity and mortality of Scottish children with inflammatory bowel disease. Q J Med 1990; 75:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24693/abstract/4\">",
"      Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 Suppl A:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24693/abstract/5\">",
"      Motil KJ, Grand RJ, Davis-Kraft L, et al. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993; 105:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24693/abstract/6\">",
"      Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988; 95:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24693/abstract/7\">",
"      Paerregaard A, Uldall Urne F. Anthropometry at the time of diagnosis in Danish children with inflammatory bowel disease. Acta Paediatr 2005; 94:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24693/abstract/8\">",
"      Markowitz J, Grancher K, Rosa J, et al. Highly destructive perianal disease in children with Crohn's disease. J Pediatr Gastroenterol Nutr 1995; 21:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24693/abstract/9\">",
"      Keljo DJ, Markowitz J, Langton C, et al. Course and treatment of perianal disease in children newly diagnosed with Crohn's disease. Inflamm Bowel Dis 2009; 15:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24693/abstract/10\">",
"      Tolia V. Perianal Crohn's disease in children and adolescents. Am J Gastroenterol 1996; 91:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24693/abstract/11\">",
"      Harty S, Fleming P, Rowland M, et al. A prospective study of the oral manifestations of Crohn's disease. Clin Gastroenterol Hepatol 2005; 3:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24693/abstract/12\">",
"      Pittock S, Drumm B, Fleming P, et al. The oral cavity in Crohn's disease. J Pediatr 2001; 138:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24693/abstract/13\">",
"      Galbraith SS, Drolet BA, Kugathasan S, et al. Asymptomatic inflammatory bowel disease presenting with mucocutaneous findings. Pediatrics 2005; 116:e439.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5865 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-D141E0F7E3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_7_24693=[""].join("\n");
var outline_f24_7_24693=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8070511\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DISEASE LOCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NUTRITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Growth failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Micronutrient deficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ORAL AND PERIANAL LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Perianal lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Oral lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Isolated orofacial and perianal findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EXTRAINTESTINAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8070511\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5865\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5865|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/6/6253\" title=\"figure 1\">",
"      Normal growth rate in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5865|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/20/35136\" title=\"picture 1\">",
"      Abscess fistulas and skin tags",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/37/26207\" title=\"picture 2\">",
"      Mucogingivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/56/7055\" title=\"picture 3\">",
"      Mucosal tag CD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/47/17151\" title=\"picture 4\">",
"      Ulceration mandibular vestibule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/28/8655\" title=\"picture 5\">",
"      Cobblestoning buccal mucosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/32/35342\" title=\"picture 6\">",
"      Lip swelling CD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5865|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/8/19595\" title=\"table 1\">",
"      Clin features Crohns children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/32/28173\" title=\"table 2\">",
"      Extraintestinal manifest IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/2/11309\" title=\"table 3\">",
"      Evaluation of child IBD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=related_link\">",
"      Clinical features and diagnosis of inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=related_link\">",
"      Definition, epidemiology, and risk factors in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=related_link\">",
"      Diagnostic approach to short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=related_link\">",
"      Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44455?source=related_link\">",
"      Genetic factors in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2794?source=related_link\">",
"      Growth failure and poor weight gain in children with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=related_link\">",
"      Nutrient deficiencies in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41722?source=related_link\">",
"      Overview of the management of Crohn's disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=related_link\">",
"      Perianal complications of Crohn's disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_7_24694="Painless thyroiditis";
var content_f24_7_24694=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Painless thyroiditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/7/24694/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24694/contributors\">",
"     Kenneth D Burman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/7/24694/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24694/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/7/24694/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24694/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/7/24694/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Painless thyroiditis is characterized by transient hyperthyroidism, followed sometimes by hypothyroidism, and then recovery (",
"    <a class=\"graphic graphic_figure graphicRef75131 \" href=\"UTD.htm?28/16/28942\">",
"     figure 1",
"    </a>",
"    ). Synonyms for this disorder include silent thyroiditis, subacute lymphocytic thyroiditis, and lymphocytic thyroiditis with spontaneously resolving hyperthyroidism. Painless thyroiditis accounts for 1 to 5 percent of cases of hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/1\">",
"     1",
"    </a>",
"    ]. It has many similarities with postpartum thyroiditis, but by definition excludes women who have a painless thyroiditis syndrome within one year after a delivery or an abortion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/15/248?source=see_link\">",
"     \"Postpartum thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and management of painless thyroiditis will be reviewed here. An overview of thyroiditis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=see_link\">",
"     \"Overview of thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Painless thyroiditis is considered a variant form of chronic autoimmune thyroiditis (Hashimoto's thyroiditis), suggesting that it is part of the spectrum of thyroid autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/2\">",
"     2",
"    </a>",
"    ]. The two disorders have some pathologic similarities (see",
"    <a class=\"local\" href=\"#H9688990\">",
"     'Pathology'",
"    </a>",
"    below), and many patients with painless thyroiditis have high serum concentrations of antithyroid peroxidase (TPO) and anti-thyroglobulin (Tg) antibodies, many have a family history of thyroid autoimmune disease, and some develop overt chronic autoimmune thyroiditis several years later [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/3\">",
"     3",
"    </a>",
"    ]. It affects women more often than men [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Painless thyroiditis is associated with specific HLA haplotypes, most often HLA-DR3, findings that suggest an inherited susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the association is considerably weaker than that between HLA-B35 and subacute thyroiditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1399?source=see_link\">",
"     \"Subacute thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors postulated to initiate painless thyroiditis include excess iodine intake and various cytokines. A syndrome very similar to this disorder can occur in patients treated with interferon-alpha, interleukin-2,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , and tyrosine kinase inhibitors. These observations raise the possibility that cytokines released in response to some (subclinical) injury or infection might initiate the disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of thyroiditis\", section on 'Drug-induced thyroiditis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Painless thyroiditis has occasionally occurred in clusters, eg, in nursery-school workers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/5\">",
"     5",
"    </a>",
"    ]. It has been reported to occur following cessation of glucocorticoids, after adrenalectomy in a patient with Cushing's syndrome, following external radiation of the neck for Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/6-8\">",
"     6-8",
"    </a>",
"    ], and in association with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/9\">",
"     9",
"    </a>",
"    ]. Painless thyroiditis has also been associated with other disorders, including lymphocytic hypophysitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/10\">",
"     10",
"    </a>",
"    ], systemic lupus erythematosus, and idiopathic thrombocytopenic purpura. However, it has not been proven that there is a causal association between any of these disorders and thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whatever factors initiate painless thyroiditis, the resulting thyroid inflammation damages thyroid follicles and activates proteolysis of the thyroglobulin stored within the follicles. The result is unregulated release of large amounts of thyroxine (T4) and triiodothyronine (T3) into the circulation resulting in clinical and biochemical hyperthyroidism. This state lasts only until the stores of thyroglobulin are exhausted, because new hormone synthesis ceases, not only because of damage to the thyroid follicular cells but also because of inhibition of thyrotropin (TSH) secretion by the high serum T4 and T3 concentrations. As the inflammation subsides, the undamaged or repaired thyroid follicles resume synthesis and secretion of thyroid hormone. There may be a transient period of hypothyroidism and increased TSH secretion before thyroid secretion becomes normal again. In a minority of patients, thyroid damage is sufficient to result in permanent hypothyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9688936\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 to 20 percent of patients with painless thyroiditis have the characteristic sequence of hyperthyroidism, followed by hypothyroidism, and then recovery (",
"    <a class=\"graphic graphic_figure graphicRef75131 \" href=\"UTD.htm?28/16/28942\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/14\">",
"     14",
"    </a>",
"    ]. Hyperthyroid symptoms usually develop over one to two weeks, and last from two to eight weeks before subsiding. The patient may have any of the common symptoms or signs of hyperthyroidism, such as weakness, fatigue, irritability, palpitations, stare and lid retraction, tachycardia and tremor. However, the symptoms are usually mild. The thyroid gland is not painful or tender, but is usually minimally diffusely enlarged and sometimes firm in texture.",
"   </p>",
"   <p>",
"    The hyperthyroid phase may be followed by recovery or by hypothyroidism (usually clinically mild or even asymptomatic) for two to eight weeks, followed by recovery. Approximately 10 percent of patients may have additional episodes of painless thyroiditis, typically occurring years apart. Eventually, however, up to 50 percent of patients develop chronic autoimmune thyroiditis with permanent hypothyroidism, goiter, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with painless thyroiditis present with symptoms of hypothyroidism (cold intolerance, constipation, fatigue), and the symptoms that are characteristic of the hyperthyroid phase are often only apparent retrospectively when the hypothyroid phase is diagnosed. Others have no symptoms or signs at all; in this latter setting, the disease is incidentally detected by routine thyroid testing and the finding of a low serum TSH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid function tests vary during the course of painless thyroiditis, and changes in serum TSH typically lag behind changes in serum free T4 and T3. During the hyperthyroid phase, patients with painless thyroiditis have moderately elevated serum free T4, normal or slightly elevated T3, and low serum TSH concentrations, but some have only low serum TSH concentrations (subclinical hyperthyroidism). In patients with painless thyroiditis, the serum T3 concentrations are not disproportionately elevated as they are in patients with Graves' hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/15\">",
"     15",
"    </a>",
"    ]. In thyroiditis, the hormones that appear in the blood from damaged follicles are in the same proportions as exist in the thyroid gland (T4&gt;&gt;T3), while in Graves&rsquo; disease thyroid deiodinase is activated, yielding a thyroidal secretory product containing relatively more T3.",
"   </p>",
"   <p>",
"    In those patients who become hypothyroid, the serum T4 concentration may be low for several days to weeks before the serum TSH concentration becomes high, because of the preceding suppression of TSH secretion. Some patients have only elevation of serum TSH levels, indicative of subclinical hypothyroidism.",
"   </p>",
"   <p>",
"    Serum antithyroid peroxidase concentrations are high in about 50 percent of patients at the time of diagnosis, but not to the extent found in Hashimoto&rsquo;s thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. The values may rise transiently in the following weeks, and then decline, but they remain elevated after thyroid function returns to normal. Other thyroid antibodies, eg, anti-TSH receptor antibodies, may occasionally be detected during the illness or soon after it, but do not appear to contribute to the thyroid dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/17\">",
"     17",
"    </a>",
"    ]. Serum thyroglobulin concentrations are high, and these elevations may persist after the recovery of thyroid function. The white blood cell count is usually normal, and the erythrocyte sedimentation rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C-reactive protein are normal or slightly increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H659111\">",
"    <span class=\"h2\">",
"     Thyroid scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the hyperthyroid phase of thyroiditis, values for thyroid radioiodine uptake are low, usually less than 1 percent, compared with high values in Graves&rsquo; hyperthyroidism. Similarly, technetium scan shows an image with a very low radiotracer accumulation, whereas the image shows increased radiotracer accumulation in Graves&rsquo; disease. These tests are extremely valuable in distinguishing painless thyroiditis from mild Graves&rsquo; hyperthyroidism. (See",
"    <a class=\"local\" href=\"#H9688949\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9689093\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is not typically part of the evaluation of painless thyroiditis. If performed for the evaluation of suspected goiter, ultrasonography shows a heterogeneous, hypoechogenic, normal-sized or slightly enlarged thyroid gland. In addition, if a thyroid ultrasound is performed during the hyperthyroid phase of thyroiditis, there will be normal or decreased Doppler flow (as compared with increased in Graves&rsquo; disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=see_link&amp;anchor=H29#H29\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\", section on 'Autoimmune thyroid disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9688990\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fine needle aspiration biopsy is not typically part of the evaluation of painless thyroiditis. If performed, fine needle aspiration of the thyroid reveals lymphocytes and macrophages, normal thyroid epithelial cells, a few damaged thyroid follicles, and masses of colloid. During recovery, lymphocytic infiltration persists, and there may be mild fibrosis, but the thyroid follicles are normal. These findings differ from those of chronic autoimmune thyroiditis in that there is more follicular disruption, but fewer lymphocytes, fewer germinal centers, and less fibrosis in painless thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9688949\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of painless thyroiditis is based upon clinical manifestations, laboratory findings and, when needed, thyroid scintigraphy. Painless thyroiditis should be considered as the cause of hyperthyroidism in any woman (who is not postpartum) or man who has had symptoms for less than two months and has a small diffuse goiter or no thyroid enlargement. This diagnosis should be strongly considered in a hyperthyroid patient who has been receiving interferon-alpha or interleukin-2. In addition, the presence of painless thyroiditis should be considered in patients with no symptoms who are found to have low serum TSH on routine testing.",
"   </p>",
"   <p>",
"    For patients in whom the clinical suspicion of hyperthyroidism is high, we measure TSH, free T4, and T3, rather than TSH alone. If a low TSH value is obtained during routine testing, serum free T4 and T3 should automatically be measured on the same specimen or, if not possible, the patient should return for follow-up testing.",
"   </p>",
"   <p>",
"    In patients with hyperthyroidism (low serum TSH, high free T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T3) and without clinical manifestations of Graves&rsquo; disease (eg, ophthalmopathy), a radioiodine uptake or technetium scan is necessary to differentiate painless thyroiditis from Graves&rsquo; disease. During the hyperthyroid phase of painless thyroiditis, values for thyroid radioiodine uptake are very low, whereas they are at the upper end of normal or high in patients with Graves&rsquo; disease. Technetium scan shows an image with a very low radiotracer accumulation, whereas the image shows increased radiotracer accumulation in Graves&rsquo; disease. In most patients with a low radioiodine uptake or low radiotracer accumulation on technetium scan, reevaluation of thyroid function tests in several weeks usually reveals more normal thyroid function, supporting the diagnosis.",
"   </p>",
"   <p>",
"    In patients with mild hyperthyroidism and a serum free T4 that is higher relative to its upper limit of normal than is the serum T3 elevation, a radioiodine uptake or technetium scan may be deferred and thyroid function monitored. If thyroid function normalizes within several weeks, the diagnosis of painless thyroiditis can be suspected, although mild Graves&rsquo; disease can also occasionally follow this course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H659104\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the hyperthyroid phase, painless thyroiditis must be distinguished from other causes of hyperthyroidism and diffuse goiter, such as Graves' disease, which is more common than painless thyroiditis, and TSH-induced hyperthyroidism (eg, TSH secreting pituitary tumor), which is less common. Painless thyroiditis can be distinguished from the latter two disorders by its shorter duration, minimal thyroid enlargement, and a low thyroid radioiodine uptake (versus the high values in Graves' hyperthyroidism and excess TSH secretion). In addition, serum TSH concentrations are inappropriately normal or elevated in patients with TSH-induced hyperthyroidism. When thyroid scintigraphy is contraindicated, painless thyroiditis and Graves&rsquo; disease may also be distinguished by measuring serum thyroid stimulating immunoglobulins (TSH receptor antibodies). Serum thyroid stimulating immunoglobulins levels are typically elevated in Graves&rsquo; hyperthyroidism but not in painless thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, on ultrasound, thyroid Doppler flow is normal or decreased in the thyrotoxic phase of silent thyroiditis and increased in Graves&rsquo; hyperthyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link&amp;anchor=H4#H4\">",
"     \"Disorders that cause hyperthyroidism\", section on 'Graves' disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Painless thyroiditis must also be distinguished from exogenous hyperthyroidism (ingesting thyroxine or thyroid hormone products), whether iatrogenic or factitious. Thyroid hormone or its active analogues have been found in various over the counter supplements and in meat products that contained thyroid gland fragments. Patients with these disorders have little or no thyroid enlargement (unless the thyroid hormone was given in hope of reducing a goiter), low thyroid radioiodine uptake values, and low serum thyroglobulin concentrations. In contrast, serum thyroglobulin levels are elevated in patients with painless thyroiditis. Careful history-taking should elicit information about thyroid hormone ingestion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=see_link&amp;anchor=H2#H2\">",
"     \"Exogenous hyperthyroidism\", section on 'Causes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During the hypothyroid phase, painless thyroiditis presents similarly to Hashimoto&rsquo;s thyroiditis. The diagnosis may be suspected if the patient recalls having had spontaneous resolving symptoms of hyperthyroidism weeks to a few months earlier. We do not routinely measure antithyroid peroxidase antibodies, since they are nonspecific and are frequently present in both diseases. If thyroid function normalizes within several weeks without thyroid hormone replacement, the diagnosis of painless thyroiditis is confirmed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link&amp;anchor=H3#H3\">",
"     \"Disorders that cause hypothyroidism\", section on 'Chronic autoimmune (Hashimoto's) thyroiditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies assessing the optimal treatment of painless thyroiditis. Treatment is based upon observational data and clinical experience. Many patients with thyroiditis need no treatment during either the hyperthyroid or the hypothyroid phases, because thyroid dysfunction is rarely severe and it is transient. However, patients who are symptomatic or who are at increased risk for atrial fibrillation should be treated with a beta-blocker during the hyperthyroid phase, unless there is a contraindication to their use. Options include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    (40 to 120 mg daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    (25 to 50 mg daily). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=see_link\">",
"     \"Beta blockers in the treatment of hyperthyroidism\"",
"    </a>",
"    .) Thyroid function should be monitored every four to eight weeks to confirm resolution of hyperthyroidism and to detect the development of hypothyroidism. Beta blockers should only be used during the hyperthyroid phase of painless thyroiditis.",
"   </p>",
"   <p>",
"    In very rare cases of severely deranged thyroid function, glucocorticoid therapy has been used successfully [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/19\">",
"     19",
"    </a>",
"    ]. There is no role for antithyroid drugs (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    ) or radioactive iodine, because the hyperthyroidism is not caused by excess thyroid hormone synthesis and because uptake of radioiodine is very low.",
"   </p>",
"   <p>",
"    An occasional patient may have sufficient symptoms of hypothyroidism to warrant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    (T4) therapy. In addition, we prefer to treat when the TSH exceeds 10",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    even in the absence of symptoms. The usual dose of T4 is 50 to 100 mcg daily. The T4 should be discontinued after three to six months. The dose can be halved and thyroid tests (TSH, free T4) reevaluated four to six weeks later. After recovery, the patient should be told of the risk of chronic autoimmune thyroiditis, its symptoms described, and periodic follow-up advised. Although abnormalities in thyroid function resolve in most patients, up to 20 percent will develop permanent hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients should also be informed about the possibility of recurrent episodes of thyroiditis, often many years in the future.",
"   </p>",
"   <p>",
"    Rare patients with recurrent episodes of painless thyroiditis may choose to have their thyroid ablated with radioiodine between episodes when they are euthyroid and the radioiodine uptake has returned to normal. However, definitive therapy is rarely necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24694/abstract/20\">",
"     20",
"    </a>",
"    ]. Radioiodine therapy during the thyrotoxic phase is not effective because the uptake of radioiodine by the thyroid is very low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/42/13986?source=see_link\">",
"       \"Patient information: Thyroiditis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H659029\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Painless thyroiditis is considered a variant form of chronic autoimmune thyroiditis (Hashimoto's thyroiditis), suggesting that it is part of the spectrum of thyroid autoimmune disease. It is characterized by transient hyperthyroidism, followed sometimes by hypothyroidism, and then recovery (",
"      <a class=\"graphic graphic_figure graphicRef75131 \" href=\"UTD.htm?28/16/28942\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of painless thyroiditis is based upon clinical manifestations, laboratory findings and, when needed, thyroid scintigraphy. For patients in whom the clinical suspicion of hyperthyroidism is high, we measure TSH, free T4, and T3. If a low TSH value is obtained during routine testing of an asymptomatic patient, serum free T4 and T3 should automatically be measured on the same specimen or, if not possible, the patient should return for follow-up testing. In patients with hyperthyroidism and without clinical manifestations of Graves&rsquo; disease (eg, ophthalmopathy), we measure 24-hour radioiodine uptake or perform a technetium scan while the patient is thyrotoxic to differentiate painless thyroiditis from Graves&rsquo; disease. (See",
"      <a class=\"local\" href=\"#H9688949\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients with thyroiditis need no treatment during either the hyperthyroid or hypothyroid phases, because thyroid dysfunction is rarely severe, and it is transient. Thyroid function tests should be monitored every four to eight weeks to confirm resolution of hyperthyroidism and to detect the development of hypothyroidism. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Beta blockers are useful to relieve bothersome palpitations or tremulousness in symptomatic hyperthyroid patients. There is no role for antithyroid drugs or radioactive iodine in the treatment of the hyperthyroid phase of postpartum thyroiditis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with symptomatic hypothyroidism require treatment with thyroxine (T4). For asymptomatic patients who have a serum TSH concentration &gt;10",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      during the hypothyroid phase, we also suggest T4 replacement (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We typically treat with 50 to 100",
"      <span class=\"nowrap\">",
"       mcg/day.",
"      </span>",
"      We continue T4 for three to six months before attempting withdrawal. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 10 percent of patients may have additional episodes of painless thyroiditis. Eventually, up to 20 percent of patients develop permanent hypothyroidism. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/1\">",
"      Ross DS. Syndromes of thyrotoxicosis with low radioactive iodine uptake. Endocrinol Metab Clin North Am 1998; 27:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/2\">",
"      Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med 2003; 348:2646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/3\">",
"      Nikolai TF, Coombs GJ, McKenzie AK. Lymphocytic thyroiditis with spontaneously resolving hyperthyroidism and subacute thyroiditis. Long-term follow-up. Arch Intern Med 1981; 141:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/4\">",
"      Farid NR, Hawe BS, Walfish PG. Increased frequency of HLA-DR3 and 5 in the syndromes of painless thyroiditis with transient thyrotoxicosis: evidence for an autoimmune aetiology. Clin Endocrinol (Oxf) 1983; 19:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/5\">",
"      Ogura T, Hirakawa S, Suzuki S, et al. Five patients with painless thyroiditis simultaneously developed in a nursery school. Endocrinol Jpn 1988; 35:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/6\">",
"      Wilkins M, Moe MM. Acute painless thyroiditis with transient thyrotoxicosis during external beam irradiation to non-Hodgkin's lymphoma of the thyroid gland. Clin Oncol (R Coll Radiol) 2001; 13:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/7\">",
"      Morita S, Ueda Y, Yokoyama N. Painless thyroiditis induced by the cessation of betamethasone. Intern Med 2001; 40:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/8\">",
"      Yamakita N, Sakata S, Hayashi H, et al. Case report: silent thyroiditis after adrenalectomy in a patient with Cushing's syndrome. Am J Med Sci 1993; 305:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/9\">",
"      Miller KK, Daniels GH. Association between lithium use and thyrotoxicosis caused by silent thyroiditis. Clin Endocrinol (Oxf) 2001; 55:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/10\">",
"      Ozawa Y, Shishiba Y. Recovery from lymphocytic hypophysitis associated with painless thyroiditis: clinical implications of circulating antipituitary antibodies. Acta Endocrinol (Copenh) 1993; 128:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/11\">",
"      Magaro M, Zoli A, Altomonte L, et al. The association of silent thyroiditis with active systemic lupus erythematosus. Clin Exp Rheumatol 1992; 10:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/12\">",
"      Nagai K, Sakata S, Takuno H, et al. A case of silent thyroiditis associated with idiopathic thrombocytopenic purpura. Endocrinol Jpn 1988; 35:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/13\">",
"      Mittra ES, McDougall IR. Recurrent silent thyroiditis: a report of four patients and review of the literature. Thyroid 2007; 17:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/14\">",
"      Samuels MH. Subacute, silent, and postpartum thyroiditis. Med Clin North Am 2012; 96:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/15\">",
"      Shigemasa C, Abe K, Taniguchi S, et al. Lower serum free thyroxine (T4) levels in painless thyroiditis compared with Graves' disease despite similar serum total T4 levels. J Clin Endocrinol Metab 1987; 65:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/16\">",
"      Woolf PD. Transient painless thyroiditis with hyperthyroidism: a variant of lymphocytic thyroiditis? Endocr Rev 1980; 1:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/17\">",
"      Morita T, Tamai H, Oshima A, et al. The occurrence of thyrotropin binding-inhibiting immunoglobulins and thyroid-stimulating antibodies in patients with silent thyroiditis. J Clin Endocrinol Metab 1990; 71:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/18\">",
"      Kamijo K. Study on cutoff value setting for differential diagnosis between Graves' disease and painless thyroiditis using the TRAb (Elecsys TRAb) measurement via the fully automated electrochemiluminescence immunoassay system. Endocr J 2010; 57:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/19\">",
"      Nikolai TF, Coombs GJ, McKenzie AK, et al. Treatment of lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Intern Med 1982; 142:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24694/abstract/20\">",
"      Ohye H. Recurrent severe painless thyroiditis requiring multiple treatments with radioactive iodine. Thyroid 2008; 18:1231.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7830 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_7_24694=[""].join("\n");
var outline_f24_7_24694=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H659029\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9688936\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H659111\">",
"      Thyroid scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9689093\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9688990\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9688949\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H659104\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H659029\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7830\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7830|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/16/28942\" title=\"figure 1\">",
"      Course of thyroiditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=related_link\">",
"      Beta blockers in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=related_link\">",
"      Disorders that cause hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=related_link\">",
"      Exogenous hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=related_link\">",
"      Overview of the clinical utility of ultrasonography in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=related_link\">",
"      Overview of thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/42/13986?source=related_link\">",
"      Patient information: Thyroiditis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/15/248?source=related_link\">",
"      Postpartum thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1399?source=related_link\">",
"      Subacute thyroiditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_7_24695="Chigger bites - leg";
var content_f24_7_24695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69469%7EDERM%2F77496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69469%7EDERM%2F77496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chigger bites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small erythematous papules are present on the lower leg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chigger bites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 453px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin lesions on a patient who sustained over 1000 chigger bites. Note the erythematous papules clustered along the waistline, a common location for chigger bites.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of JF Butler, Professor Emeritus, University of Florida.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_7_24695=[""].join("\n");
var outline_f24_7_24695=null;
var title_f24_7_24696="Amebiasis life cycle";
var content_f24_7_24696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Amebiasis life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 610px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cysts and trophozoites are passed in feces",
"    <strong>",
"     (1)",
"    </strong>",
"    . Cysts are typically found in formed stool, whereas trophozoites are typically found in diarrheal stool. Infection by Entamoeba histolytica occurs by ingestion of mature cysts",
"    <strong>",
"     (2)",
"    </strong>",
"    in fecally contaminated food, water, or hands. Excystation",
"    <strong>",
"     (3)",
"    </strong>",
"    occurs in the small intestine and trophozoites",
"    <strong>",
"     (4)",
"    </strong>",
"    are released, which migrate to the large intestine. The trophozoites multiply by binary fission and produce cysts",
"    <strong>",
"     (5)",
"    </strong>",
"    , and both stages are passed in the feces",
"    <strong>",
"     (1)",
"    </strong>",
"    . Because of the protection conferred by their walls, the cysts can survive days to weeks in the external environment and are responsible for transmission. Trophozoites passed in the stool are rapidly destroyed once outside the body, and if ingested would not survive exposure to the gastric environment. In many cases, the trophozoites remain confined to the intestinal lumen (",
"    <strong>",
"     A:",
"    </strong>",
"    noninvasive infection) of individuals who are asymptomatic carriers, passing cysts in their stool. In some patients the trophozoites invade the intestinal mucosa (",
"    <strong>",
"     B:",
"    </strong>",
"    intestinal disease), or, through the bloodstream, extraintestinal sites such as the liver, brain, and lungs (",
"    <strong>",
"     C:",
"    </strong>",
"    extraintestinal disease), with resultant pathologic manifestations. It has been established that the invasive and noninvasive forms represent two separate species, respectively E. histolytica and E. dispar. These two species are morphologically indistinguishable unless E. histolytica is observed with ingested red blood cells (erythrophagocystosis). Transmission can also occur through exposure to fecal matter during sexual contact (in which case not only cysts, but also trophozoites could prove infective).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Amebiasis. Available at:",
"     <a href=\"file://dpd.cdc.gov/DPDX/HTML/Amebiasis.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/DPDX/HTML/Amebiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_7_24696=[""].join("\n");
var outline_f24_7_24696=null;
var title_f24_7_24697="Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis";
var content_f24_7_24697=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/7/24697/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24697/contributors\">",
"     Paul F Dellaripa, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24697/contributors\">",
"     Marc L Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/7/24697/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24697/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24697/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/7/24697/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24697/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/7/24697/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/7/24697/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatomyositis (DM) and polymyositis (PM) are classified as idiopathic inflammatory myopathies. Among patients with DM or PM, interstitial lung disease (ILD) is a major cause of morbidity and mortality. A general approach to the evaluation of ILD is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with DM or PM, ILD must be distinguished from other causes of pulmonary disease:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Drug-induced pneumonitis",
"     </li>",
"     <li>",
"      Pneumomediastinum",
"     </li>",
"     <li>",
"      Respiratory muscle weakness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations and evaluation of ILD associated with DM and PM will be reviewed here. The treatment of respiratory diseases in DM and PM and the clinical manifestations and diagnosis of myositis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8313?source=see_link\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29368?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of ILD varies widely (from 20 to 80 percent) among case series of patients with PM and DM [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. This variability is related to several factors, including the methods used to identify ILD (eg, lower rates if high resolution computed tomography is not used), the proportions of the different subsets of muscle disease (eg, normal versus elevated muscle enzyme levels, presence of antisynthetase antibodies), and the presence of an underlying malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/1-3,5-12\">",
"     1-3,5-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain subsets of DM and PM appear to be associated with different frequencies of ILD. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ILD may be more common in patients with normal serum creatine kinase (CK) levels (eg, 62 versus 20 percent in patients with high serum CK levels in one report) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective series of 90 patients with DM or PM and serum anti-Jo-1 antibodies, ILD was identified in 86 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Laboratory testing'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      ILD is less common in patients with inflammatory myositis associated with malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/12,14,15\">",
"       12,14,15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=see_link\">",
"       \"Malignancy in dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathologic appearance of ILD in DM and PM reflects the patterns of lung pathology associated with the idiopathic interstitial pneumonias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The histologic patterns of ILD that have been observed in biopsy and autopsy studies include [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonspecific interstitial pneumonia (NSIP) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42393?source=see_link\">",
"       \"Nonspecific interstitial pneumonia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Usual interstitial pneumonia (UIP) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link&amp;anchor=H3#H3\">",
"       \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\", section on 'Usual interstitial pneumonia'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Organizing pneumonia, also known as bronchiolitis obliterans with organizing pneumonia (BOOP) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link\">",
"       \"Cryptogenic organizing pneumonia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diffuse alveolar damage (DAD), seen in patients with acute interstitial pneumonia (AIP) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22792?source=see_link\">",
"       \"Acute interstitial pneumonia (Hamman-Rich syndrome)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These patterns are indistinguishable from the idiopathic interstitial pneumonias and the forms of ILD that occur in other rheumatic diseases such as systemic lupus erythematosus, rheumatoid arthritis, and scleroderma. Details related to the specific histopathologic features of these subtypes of ILD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although data are limited, there is a general feeling that NSIP is the most common histopathologic pattern of ILD in patients with DM and PM. The relative frequency of the different histopathologic patterns was evaluated in a series of 22 patients with DM or PM who underwent lung biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/15\">",
"     15",
"    </a>",
"    ]. NSIP was by far the most common finding (18 patients), followed by DAD (two patients), UIP (one patient), and BOOP (one patient).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The respiratory manifestations of ILD in patients with PM or DM parallel those described for patients with the idiopathic interstitial pneumonias, although the muscle weakness associated with these myopathies may influence the degree of dyspnea and risk of aspiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19\">",
"     'Respiratory muscle weakness'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The temporal relationship between the onset of ILD and myositis is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/16\">",
"     16",
"    </a>",
"    ]. ILD can precede the diagnosis of myositis by months or years, appear simultaneously with myositis, or develop after the muscle disease, usually within the first few months from the onset of weakness.",
"   </p>",
"   <p>",
"    Patients with ILD typically complain of dyspnea and a nonproductive cough and may have fever and arthralgias [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/18\">",
"     18",
"    </a>",
"    ]. However, some patients are asymptomatic and others attribute dyspnea to muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/18\">",
"     18",
"    </a>",
"    ]. Among patients with amyopathic dermatomyositis, ILD can present with rapid onset and progression [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/19\">",
"     19",
"    </a>",
"    ]. The Raynaud phenomenon occurs in 10 to 20 percent of cases of DM and PM [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lung examination may be clear on chest auscultation or reveal dry bibasilar crackles. These findings are nonspecific for ILD. In patients who have not yet been diagnosed with PM or DM, the presence of these disorders may be suspected in those who also have proximal muscle weakness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abnormal nailfold capillary microscopy. The other signs and symptoms of PM and DM are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A subset of patients may present with a constellation of clinical features, including myositis, ILD, inflammatory polyarthritis, mechanic's hands, fever, and Raynaud phenomenon, called the &ldquo;antisynthetase syndrome&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/2,6,16,22\">",
"     2,6,16,22",
"    </a>",
"    ]. This syndrome is generally considered present in patients who have two or more of the above clinical features as well as antibodies to one or more of the aminoacyl-transfer RNA synthetases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/2,22-26\">",
"     2,22-26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Laboratory testing'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infection should be suspected when the patient is febrile or when dyspnea and radiographic appearance worsen over a few days, particularly in patients on immunosuppressive medication. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main role of laboratory testing is to establish the diagnosis of the underlying myositis. For patients who do not have a confirmed diagnosis of PM or DM, we usually obtain serum muscle enzymes (eg, AST, ALT, aldolase, creatine kinase), an antinuclear antibody test, and an anti-Jo-1 antibody (anti-histidyl-transfer (t) RNA synthetase). If the anti-Jo-1 antibody is negative, we obtain a panel of the other specific myositis antibodies, such as those directed against other tRNA synthetases (eg, anti-PL-7 [anti-threonyl-tRNA synthetase], anti-PL-12 [anti-alanyl-tRNA synthetase]). The laboratory evaluation of patients with DM or PM is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of individual myositis antibodies may play a role in determining the disease manifestations in a given patient, although this is still an area of investigation. The presence of antisynthetase antibodies appears to be associated with a greater likelihood of ILD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/4,13,15,27,28\">",
"     4,13,15,27,28",
"    </a>",
"    ]. As an example, in a series of 90 patients with anti-Jo-1 antibodies, the incidence of ILD approached 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/13\">",
"     13",
"    </a>",
"    ]. In a separate series of 95 patients with antisynthetase syndrome, ILD was present in 68 percent of those with anti-Jo-1 antibodies and 90 percent of those with anti-PL-7 or anti-PL-12 antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other noninvasive markers have been used to assess prognosis and guide disease management, but their clinical role is not established. These include HLA class II associations, serum biomarkers such as Kerbs von Lungren factor (KL-6), surfactant protein D (SP-D), and serum chemokine levels (eg, CXCL9 and CXCL10) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/13,29-32\">",
"     13,29-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A conventional chest radiograph is typically obtained when the patient has cough or dyspnea, crackles on lung exam, abnormal pulmonary function tests, or positive tests for anti-transfer RNA synthetase antibodies. The most common findings on chest radiography are diffuse reticular and nodular opacities, predominantly at the lung bases. Patients with fulminant disease may have patchy, \"ground glass\" opacities (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83490 \" href=\"UTD.htm?4/40/4738\">",
"     image 1",
"    </a>",
"    ). Pleural effusions are not seen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High resolution computed tomography (HRCT, also known as thin-section CT) is a more sensitive technique than conventional chest radiography and can be used to characterize interstitial changes that are seen on chest radiography [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/25\">",
"     25",
"    </a>",
"    ]. Typical HRCT changes include patchy ground glass opacities and septal thickening (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83491 \" href=\"UTD.htm?16/20/16711\">",
"     image 2",
"    </a>",
"    ). In addition, we typically obtain a CT scan in patients with amyopathic dermatomyositis if there is clinical suspicion of ILD or lung malignancy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87914 \" href=\"UTD.htm?8/50/8997\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    HRCT is performed in the supine and prone positions to determine if interstitial opacities are due to gravity-induced atelectasis. Radiographic patterns reflect the underlying pathology and include ground glass opacification, basilar consolidation, septal thickening, honeycombing, and irregular linear opacities [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Histopathology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link&amp;anchor=H12#H12\">",
"     \"High resolution computed tomography of the lungs\", section on 'Ground glass opacification'",
"    </a>",
"    .) As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ground glass opacification suggests cellular nonspecific interstitial pneumonia (NSIP)",
"     </li>",
"     <li>",
"      Predominantly reticular changes suggest fibrotic NSIP or usual interstitial pneumonia (UIP)",
"     </li>",
"     <li>",
"      Honeycombing suggests UIP",
"     </li>",
"     <li>",
"      Patchy consolidative opacities are suggestive of organizing pneumonia",
"      <span class=\"nowrap\">",
"       (OP)/bronchiolitis",
"      </span>",
"      obliterans organizing pneumonia (BOOP) or infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HRCT has the advantage of being noninvasive and repeatable, permitting an assessment of response to therapy. In addition, sampling error is unlikely because the entire lung is imaged, whereas sampling error may be a problem with lung biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/33-36\">",
"     33-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function tests (PFTs) are used to help identify the cause of dyspnea (eg, ILD versus respiratory muscle weakness) and to assess the severity of respiratory impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=see_link\">",
"     \"Diffusing capacity for carbon monoxide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with ILD, PFTs typically demonstrate a restrictive pattern (low forced vital capacity [FVC] and low total lung capacity [TLC]) and a diminished diffusing capacity. Patients with early interstitial lung disease may have normal or near-normal PFTs, except for a mild decrease in oxygen saturation with 6 minute walk testing.",
"   </p>",
"   <p>",
"    In contrast, patients with respiratory muscle weakness without ILD may have a restrictive pattern, but will typically have a normal diffusing capacity and clear lung fields on HRCT. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Respiratory muscle weakness'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopy with bronchoalveolar lavage can help to exclude other causes of interstitial opacities, such as infection and alveolar hemorrhage. This is particularly important in patients who present with a worsening of pulmonary function after treatment with immunosuppressive drugs or rapid deterioration in lung function. Transbronchial biopsy may be useful to assess for fungal infections, but has little if any role in diagnosing the pathologic type of ILD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with known DM or PM, the diagnosis of interstitial lung disease (ILD) is usually suspected on the combination of clinical presentation, laboratory tests, chest radiograph, high resolution CT (HRCT) scan, and pulmonary function tests as described above. Because patients with DM or PM have many other potential causes of dyspnea (eg, anemia, lung infection, drug-induced pneumonitis, spontaneous pneumomediastinum, or respiratory muscle weakness), radiographic imaging and pulmonary function testing are necessary to confirm the presence of ILD. Radiographic imaging also helps to characterize the pattern of ILD.",
"   </p>",
"   <p>",
"    In patients with ILD, but without known inflammatory myositis, underlying DM or PM may be suspected on the basis of cutaneous manifestations (eg, Gottron's papules, \"mechanic's hands\"), symmetric proximal muscle weakness, capillary microscopic changes, or laboratory testing. In rare cases, ILD may be the first manifestation of a rheumatic disease such as dermatomyositis or the antisynthetase syndrome. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Laboratory testing'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the clinical course or imaging studies are atypical (eg, progressing more rapidly, flaring while on immunosuppressive therapy), bronchoscopy with bronchoalveolar lavage (BAL) or lung biopsy may be indicated. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical features'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other complications of DM and PM and the immunosuppressive therapy used to treat myositis or interstitial lung disease (ILD) may cause dyspnea and cough, independent of or in addition to ILD. These conditions (infection, drug-induced pneumonitis, spontaneous pneumomediastinum, and respiratory muscle weakness) should be considered in the initial differential diagnosis of ILD and should also be considered when a patient with ILD and DM or PM suffers clinical worsening or fails to respond to treatment.",
"   </p>",
"   <p>",
"    Cardiac involvement due to DM or PM is rarely a cause of clinically apparent heart failure, but should also be considered in the differential diagnosis of dyspnea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung infection is a common and potentially lethal complication of DM and PM. Several factors may contribute to this problem [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/6,22,38,39\">",
"     6,22,38,39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory muscle weakness can lead to a weak cough, atelectasis, and consequently, a predisposition to bacterial pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link\">",
"       \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oropharyngeal and esophageal dysfunction may increase the risk of aspiration pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=see_link\">",
"       \"Aspiration pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lymphopenia affecting both T and B cells is a frequent finding in DM, even before the initiation of immunosuppressive treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/41\">",
"       41",
"      </a>",
"      ]. In one series, patients with lymphopenia had an increased frequency of pneumonia compared those with normal cell counts.",
"     </li>",
"     <li>",
"      Therapy with high-dose glucocorticoids and other immunosuppressive agents increases the risk of opportunistic infections including Pneumocystis jirovecii (previously called P. carinii), other fungi, and Nocardia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/24,41-44\">",
"       24,41-44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Features that suggest infection include a rapid worsening of respiratory symptoms and radiographic abnormalities, a productive cough, fever, and leukocytosis. Evaluation generally includes blood cultures and sputum smear and culture for bacteria, fungi, and mycobacteria. Induced sputum can be obtained for P. jirovecii immunofluorescence. If initial studies are unrevealing, bronchoscopy with bronchoalveolar lavage and transbronchial biopsy may be needed to identify the infecting organism. Often, empiric antibiotic therapy is initiated while waiting for the results of these studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Drug-induced pneumonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with inflammatory myopathy, drug-induced ILD needs to be differentiated from ILD associated with the underlying myopathy. Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    have been associated with the development of drug-induced ILD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    pneumonitis can occur at any dose and at any time during a patient's use of the medication, although most cases occur within the first year. Discontinuation of the drug usually leads to rapid improvement. Methotrexate pneumonitis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following issues deserve emphasis in patients with DM and PM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations are similar to those seen with ILD or infection. One exception is that basilar predominance of infiltrates on chest radiograph is unusual in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      pneumonitis and is common in ILD associated with DM and PM. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lung biopsy does not distinguish between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      pneumonitis and an ILD caused by the underlying myositis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/42\">",
"       42",
"      </a>",
"      ]. Infection, which is another major consideration in the differential diagnosis, can usually be excluded by bronchoalveolar lavage.",
"     </li>",
"     <li>",
"      Peripheral eosinophilia, when present, suggests",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      -induced pneumonitis rather than ILD due to the underlying myositis. However, this finding is nonspecific and its sensitivity is unknown, particularly in patients treated with glucocorticoids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    -induced pneumonitis is less common than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -induced pneumonitis. Two distinct clinical patterns of pulmonary toxicity have been described: an acute pneumonitis that occurs early in the course of treatment (usually in the first six months), and a chronic, progressive, fibrotic process that occurs after prolonged therapy. The former usually improves gradually after discontinuation of cyclophosphamide, whereas the latter tends to be progressive despite drug discontinuation. The clinical features, diagnosis, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=see_link&amp;anchor=H2#H2\">",
"     \"Cyclophosphamide pulmonary toxicity\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=see_link&amp;anchor=H8#H8\">",
"     \"Cyclophosphamide pulmonary toxicity\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=see_link&amp;anchor=H14#H14\">",
"     \"Cyclophosphamide pulmonary toxicity\", section on 'Treatment and prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Spontaneous pneumomediastinum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous pneumomediastinum is a rare but serious complication of inflammatory myositis and occurs more commonly in DM than PM (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87913 \" href=\"UTD.htm?42/24/43395\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/45\">",
"     45",
"    </a>",
"    ]. Virtually all patients with DM or PM who develop a pneumomediastinum have ILD, and the pneumomediastinum is occasionally the presenting clinical manifestation of ILD. The management of spontaneous pneumomediastinum in DM and PM is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8313?source=see_link&amp;anchor=H18#H18\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Treatment\", section on 'Spontaneous pneumomediastinum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately one-half of patients with DM who develop a pneumomediastinum have amyopathic DM [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is thought that the main cause of pneumomediastinum in patients with DM and PM is architectural distortion of lung tissue due to ILD. Another possible explanation is that vasculopathic lesions within the respiratory tract may result in bronchial or alveolar wall injury and subsequent air leakage. This theory is based upon the association of pneumomediastinum with the cutaneous vasculopathic lesions that can be seen in DM and the finding of endobronchial areas of subepithelial necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical presentation of pneumomediastinum is the acute onset of retrosternal chest pain with neck and face swelling due to subcutaneous emphysema. Some patients also complain of dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition, patients often have evidence of a flare of their underlying DM or PM with fever, worsening skin manifestations, Raynaud's phenomenon, or weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pneumomediastinum is often visible on a plain chest radiograph as a narrow streak of air along the descending aorta, left hilum, and left cardiac shadow. This streak may extend up into the neck. When mediastinal air outlines the superior surface of the diaphragm and separates it from the heart, the finding is known as the \"continuous diaphragm sign.\" Subcutaneous air is often seen in the neck.",
"   </p>",
"   <p>",
"    A high resolution CT (HRCT) scan is usually performed to delineate the extent and characteristics of the ILD. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Respiratory muscle weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory muscle weakness can complicate both DM and PM and must be considered in the differential diagnosis for patients with worsening dyspnea without worsening radiographic opacities. Typical inflammatory myopathic changes have been documented in the diaphragm, intercostal muscles, and accessory muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/6\">",
"     6",
"    </a>",
"    ]. The severity of impairment ranges from asymptomatic to respiratory failure.",
"   </p>",
"   <p>",
"    Estimates of prevalence have varied from 4 to 78 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/6,7,48,49\">",
"     6,7,48,49",
"    </a>",
"    ]. This variation is largely dependent on the method used to assess respiratory involvement (eg, symptom report, pulmonary function tests, or transdiaphragmatic pressures), as respiratory muscle weakness may be subclinical in patients whose activity level is reduced by skeletal muscle weakness. As an example, one study evaluated diaphragm strength in twelve patients with inflammatory myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/48\">",
"     48",
"    </a>",
"    ]. Static inspiratory and expiratory pressures, as well as mouth and transdiaphragmatic pressure responses to bilateral phrenic nerve stimulation were assessed. Diaphragm weakness was noted in 78 percent.",
"   </p>",
"   <p>",
"    Respiratory muscle weakness is more likely to be seen in patients with more profound skeletal muscle weakness, so the characteristics of the population studied may also affect the reported prevalence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic patients may complain of dyspnea, orthopnea, insomnia, daytime sleepiness, and impaired cognition. Symptoms and signs of bulbar muscle weakness (eg, difficulty swallowing, dysarthria, nasal speech) may also be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link&amp;anchor=H2#H2\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypercapnic respiratory failure caused by diaphragmatic muscle weakness has been reported in PM and DM, rarely as the presenting manifestation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Objective physiologic testing is necessary to confirm and monitor respiratory muscle weakness and usually includes measurement of forced vital capacity (FVC), supine vital capacity, maximum voluntary ventilation (MVV), maximal inspiratory pressure, maximum expiratory pressure, and gas transfer. The interpretation of these tests is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link&amp;anchor=H7#H7\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When respiratory muscle weakness is identified, the adequacy of oxygenation should be assessed when the patient is at rest, during exertion, and during sleep.",
"   </p>",
"   <p>",
"    The arterial carbon dioxide tension (PaCO2) should be assessed in the following situations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/7/24697/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complaint of daytime sleepiness",
"     </li>",
"     <li>",
"      Maximal inspiratory and expiratory pressures are less than 30 percent of normal",
"     </li>",
"     <li>",
"      FVC is less than 55 percent of predicted",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of respiratory muscle weakness in DM and PM follows the regimen used for skeletal myositis and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link&amp;anchor=H7#H7\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\", section on 'Initial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Supportive care for patients with respiratory muscle weakness includes supplemental oxygen, noninvasive positive pressure ventilation (NPPV), and cough assistance. The decisions about when and where to initiate NPPV and cough assistance measures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3528?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41543?source=see_link\">",
"     \"Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=see_link\">",
"       \"Patient information: Myositis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ILD occurs in approximately 40 percent of patients with dermatomyositis (DM) or polymyositis (PM); it may be chronic and slowly progressive or acute and rapidly progressive. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several histologic patterns of ILD are associated with DM and PM: nonspecific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), organizing pneumonia (OP, also known as bronchiolitis obliterans with organizing pneumonia [BOOP]), and acute interstitial pneumonia (AIP, also known as diffuse alveolar damage [DAD]). The presence of NSIP or OP patterns on HRCT or on lung biopsy generally portends a more favorable response to treatment than a UIP pattern. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ILD in DM and PM can usually be established based on the clinical presentation, chest imaging studies, and pulmonary function tests. Lung biopsy is usually not necessary unless there is diagnostic uncertainty despite these noninvasive studies. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with DM or PM who experience deteriorating pulmonary status, lung infection, drug-induced lung toxicity, spontaneous pneumomediastinum and respiratory muscle weakness should also be considered in the differential of deteriorating pulmonary function, particularly when the deterioration occurs over days to weeks instead of months. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with DM or PM have an increased incidence of pulmonary infection for several reasons, including ineffective cough due to respiratory muscle weakness, aspiration related to esophageal dysfunction, and immunosuppressive therapy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , medications that are commonly used to treat myositis in DM and PM, can rarely cause drug-induced pneumonitis. For patients with ILD caused or exacerbated by methotrexate or cyclophosphamide, we recommend drug discontinuation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Drug-induced pneumonitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"       \"Methotrexate-induced lung injury\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=see_link\">",
"       \"Cyclophosphamide pulmonary toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Spontaneous pneumomediastinum is a rare but serious complication of DM and, less commonly, PM. It typically occurs in the setting of worsening ILD, so the presence and severity of underlying ILD should be assessed, usually with HRCT scanning. Management usually involves supportive care (eg, rest, observation, and supplemental oxygen) and treatment of ILD. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Spontaneous pneumomediastinum'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8313?source=see_link\">",
"       \"Interstitial lung disease in dermatomyositis and polymyositis: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intercostal and diaphragmatic muscle weakness can develop in patients with DM or PM and contribute to respiratory insufficiency. The evaluation of respiratory muscle weakness includes tests of forced vital capacity, supine vital capacity, maximum voluntary ventilation, maximal inspiratory pressure, and maximum expiratory pressure. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Respiratory muscle weakness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myositis affecting respiratory muscles is treated with the same medication regimen as skeletal muscle involvement with DM or PM. Treatment options for inflammatory myositis are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link&amp;anchor=H7#H7\">",
"       \"Initial treatment of dermatomyositis and polymyositis in adults\", section on 'Initial therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of ILD in patients with DM or PM is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8313?source=see_link\">",
"       \"Interstitial lung disease in dermatomyositis and polymyositis: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/1\">",
"      Marie I, Hachulla E, Ch&eacute;rin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/2\">",
"      Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/3\">",
"      Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008; 59:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/4\">",
"      Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 2010; 138:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/5\">",
"      Nawata Y, Kurasawa K, Takabayashi K, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Rheumatol 1999; 26:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/6\">",
"      Dickey BF, Myers AR. Pulmonary disease in polymyositis/dermatomyositis. Semin Arthritis Rheum 1984; 14:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/7\">",
"      Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/8\">",
"      Frazier AR, Miller RD. Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest 1974; 65:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/9\">",
"      Salmeron G, Greenberg SD, Lidsky MD. Polymyositis and diffuse interstitial lung disease. A review of the pulmonary histopathologic findings. Arch Intern Med 1981; 141:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/10\">",
"      Hochberg MC, Feldman D, Stevens MB. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1986; 15:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/11\">",
"      Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985; 12:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/12\">",
"      Nambu Y, Mouri M, Toga H, et al. Gender and underlying diseases affect the frequency of the concurrence of adult polymyositis/dermatomyositis and interstitial pneumonia. Chest 1994; 106:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/13\">",
"      Richards TJ, Eggebeen A, Gibson K, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum 2009; 60:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/14\">",
"      Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 2001; 144:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/15\">",
"      Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/16\">",
"      Schwarz MI, Matthay RA, Sahn SA, et al. Interstitial lung disease in polymyositis and dermatomyositis: analysis of six cases and review of the literature. Medicine (Baltimore) 1976; 55:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/17\">",
"      Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV. Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990; 141:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/18\">",
"      Tillie-Leblond I, Wislez M, Valeyre D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008; 63:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/19\">",
"      Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/20\">",
"      Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004; 63:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/21\">",
"      Parodi A, Caproni M, Marzano AV, et al. Dermatomyositis in 132 patients with different clinical subtypes: cutaneous signs, constitutional symptoms and circulating antibodies. Acta Derm Venereol 2002; 82:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/22\">",
"      Arsura EL, Greenberg AS. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Semin Arthritis Rheum 1988; 18:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/23\">",
"      Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 2009; 136:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/24\">",
"      Lakhanpal, S, Lie, JT, Conn, DL, Martin II, WJ. Pulmonary disease in polymyositis/dermatomyositis: A clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis 1986; 46:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/25\">",
"      Padley SP, Hansell DM, Flower CD, Jennings P. Comparative accuracy of high resolution computed tomography and chest radiography in the diagnosis of chronic diffuse infiltrative lung disease. Clin Radiol 1991; 44:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/26\">",
"      Kalluri M, Sahn SA, Oddis CV, et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 2009; 135:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/27\">",
"      Marie I, Josse S, Decaux O, et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 2012; 11:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/28\">",
"      Labirua-Iturburu A, Selva-O'Callaghan A, Vincze M, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore) 2012; 91:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/29\">",
"      Nakajima H, Harigai M, Hara M, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol 2000; 27:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/30\">",
"      Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med 2006; 260:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/31\">",
"      Chinoy H, Salway F, Fertig N, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006; 8:R13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/32\">",
"      Kum&aacute;novics G, Minier T, Radics J, et al. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol 2008; 26:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/33\">",
"      Wells AU, du Bois RM. Bronchiolitis in association with connective tissue disorders. Clin Chest Med 1993; 14:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/34\">",
"      Mino M, Noma S, Taguchi Y, et al. Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT. AJR Am J Roentgenol 1997; 169:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/35\">",
"      Akira M, Hara H, Sakatani M. Interstitial lung disease in association with polymyositis-dermatomyositis: long-term follow-up CT evaluation in seven patients. Radiology 1999; 210:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/36\">",
"      Arakawa H, Yamada H, Kurihara Y, et al. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest 2003; 123:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/37\">",
"      Morganroth PA, Kreider ME, Okawa J, et al. Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations. Arch Dermatol 2010; 146:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/38\">",
"      Braun NM, Arora NS, Rochester DF. Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies. Thorax 1983; 38:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/39\">",
"      Astudillo LM, Carreiro M, Sailler L, et al. Hypercapnic coma due to diaphragmatic involvement in a patient with dermatomyositis. Clin Exp Rheumatol 2001; 19:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/40\">",
"      Oh TH, Brumfield KA, Hoskin TL, et al. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc 2007; 82:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/41\">",
"      Viguier M, Fou&eacute;r&eacute; S, de la Salmoni&egrave;re P, et al. Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine (Baltimore) 2003; 82:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/42\">",
"      Sostman HD, Matthay RA, Putman CE, Smith GJ. Methotrexate-induced pneumonitis. Medicine (Baltimore) 1976; 55:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/43\">",
"      Marie I, Hachulla E, Ch&eacute;rin P, et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005; 53:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/44\">",
"      Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol 1996; 23:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/45\">",
"      Le Goff B, Ch&eacute;rin P, Cantagrel A, et al. Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. Arthritis Rheum 2009; 61:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/46\">",
"      Kono H, Inokuma S, Nakayama H, Suzuki M. Pneumomediastinum in dermatomyositis: association with cutaneous vasculopathy. Ann Rheum Dis 2000; 59:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/47\">",
"      Caceres M, Ali SZ, Braud R, et al. Spontaneous pneumomediastinum: a comparative study and review of the literature. Ann Thorac Surg 2008; 86:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/48\">",
"      Teixeira A, Cherin P, Demoule A, et al. Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies. Neuromuscul Disord 2005; 15:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/7/24697/abstract/49\">",
"      Selva-O'Callaghan A, Labrador-Horrillo M, Mu&ntilde;oz-Gall X, et al. Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus 2005; 14:534.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4304 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-75F91836D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_7_24697=[""].join("\n");
var outline_f24_7_24697=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Drug-induced pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Spontaneous pneumomediastinum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Respiratory muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4304\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4304|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/40/4738\" title=\"diagnostic image 1\">",
"      Chest x-ray of polymyositis interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/20/16711\" title=\"diagnostic image 2\">",
"      Polymyositis interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/50/8997\" title=\"diagnostic image 3\">",
"      Interstitial lung disease in amyopathic dermatomyositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/24/43395\" title=\"diagnostic image 4\">",
"      Pneumomediastinum in amyopathic dermatomyositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22792?source=related_link\">",
"      Acute interstitial pneumonia (Hamman-Rich syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=related_link\">",
"      Cyclophosphamide pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=related_link\">",
"      Diffusing capacity for carbon monoxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8313?source=related_link\">",
"      Interstitial lung disease in dermatomyositis and polymyositis: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=related_link\">",
"      Malignancy in dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42393?source=related_link\">",
"      Nonspecific interstitial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29368?source=related_link\">",
"      Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=related_link\">",
"      Patient information: Myositis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41543?source=related_link\">",
"      Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3528?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_7_24698="Aspirin: Drug information";
var content_f24_7_24698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aspirin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"    see \"Aspirin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"    see \"Aspirin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ascriptin&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Ascriptin&reg; Regular Strength [OTC];",
"     </li>",
"     <li>",
"      Aspercin [OTC];",
"     </li>",
"     <li>",
"      Aspergum&reg; [OTC];",
"     </li>",
"     <li>",
"      Aspir-low [OTC];",
"     </li>",
"     <li>",
"      Aspirtab [OTC];",
"     </li>",
"     <li>",
"      Bayer&reg; Aspirin Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Bayer&reg; Aspirin Regimen Adult Low Strength [OTC];",
"     </li>",
"     <li>",
"      Bayer&reg; Aspirin Regimen Children's [OTC];",
"     </li>",
"     <li>",
"      Bayer&reg; Aspirin Regimen Regular Strength [OTC];",
"     </li>",
"     <li>",
"      Bayer&reg; Genuine Aspirin [OTC];",
"     </li>",
"     <li>",
"      Bayer&reg; Plus Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Bayer&reg; Women's Low Dose Aspirin [OTC];",
"     </li>",
"     <li>",
"      Buffasal [OTC];",
"     </li>",
"     <li>",
"      Bufferin&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Bufferin&reg; [OTC];",
"     </li>",
"     <li>",
"      Buffinol [OTC];",
"     </li>",
"     <li>",
"      Ecotrin&reg; Arthritis Strength [OTC];",
"     </li>",
"     <li>",
"      Ecotrin&reg; Low Strength [OTC];",
"     </li>",
"     <li>",
"      Ecotrin&reg; [OTC];",
"     </li>",
"     <li>",
"      Halfprin&reg; [OTC];",
"     </li>",
"     <li>",
"      St Joseph&reg; Adult Aspirin [OTC];",
"     </li>",
"     <li>",
"      Tri-Buffered Aspirin [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F137094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Asaphen;",
"     </li>",
"     <li>",
"      Asaphen E.C.;",
"     </li>",
"     <li>",
"      Entrophen&reg;;",
"     </li>",
"     <li>",
"      Novasen;",
"     </li>",
"     <li>",
"      Praxis ASA EC 81 Mg Daily Dose",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F137145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiplatelet Agent;",
"     </li>",
"     <li>",
"      Salicylate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F137098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     For most cardiovascular uses, typical maintenance dosing of aspirin is 81 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute coronary syndrome (ST-segment elevation myocardial infarction [STEMI], unstable angina (UA)/non-ST-segment elevation myocardial infarction [NSTEMI]):",
"     </b>",
"     Oral: Initial: 162-325 mg given on presentation (patient should chew nonenteric-coated aspirin especially if not taking before presentation); for patients unable to take oral, may use rectal suppository (300 mg). Maintenance (secondary prevention): 75-162 mg once daily indefinitely (Anderson, 2007; Antman, 2004).",
"     <b>",
"      Note:",
"     </b>",
"     When aspirin is used with ticagrelor, the recommended maintenance dose of aspirin is 81 mg/day (Jneid, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     UA/NSTEMI: Concomitant antiplatelet therapy (Jneid, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      If invasive strategy chosen:",
"     </i>",
"     Aspirin is recommended in combination with either clopidogrel, ticagrelor, (or prasugrel if at the time of PCI) or an I.V. GP IIb/IIIa inhibitor (if given before PCI, eptifibatide and tirofiban are preferred agents).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      If noninvasive strategy chosen:",
"     </i>",
"     Aspirin is recommended in combination with clopidogrel or ticagrelor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Analgesic and antipyretic:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 325-650 mg every 4-6 hours up to 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal: 300-600 mg every 4-6 hours up to 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anti-inflammatory:",
"     </b>",
"     Oral: Initial: 2.4-3.6 g/day in divided doses; usual maintenance: 3.6-5.4 g/day; monitor serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aortic valve repair (unlabeled use):",
"     </b>",
"     Oral: 50-100 mg once daily (Guyatt, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atrial fibrillation (in patients not candidates for oral anticoagulation or at low risk of ischemic stroke) (unlabeled use):",
"     </b>",
"     Oral: 75-325 mg once daily (Furie, 2011; Fuster, 2006).",
"     <b>",
"      Note:",
"     </b>",
"     Combination therapy with clopidogrel has been suggested over aspirin alone for those patients who are unsuitable for or choose not to take oral anticoagulant for reasons other than concerns for bleeding (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      As an alternative to adjusted-dose warfarin in patients with atrial fibrillation and mitral stenosis:",
"     </i>",
"     75-325 mg once daily with (preferred) or without clopidogrel (Guyatt, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CABG:",
"     </b>",
"     Oral: 100-325 mg once daily initiated either preoperatively or within 6 hours postoperatively; continue indefinitely (Hillis, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Carotid artery stenosis (unlabeled use):",
"     </b>",
"     Oral: 75-100 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     When symptomatic (including recent carotid endarterectomy), the use of clopidogrel or aspirin/extended-release dipyridamole has been suggested over aspirin alone (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Coronary artery disease (CAD), established:",
"     </b>",
"     Oral: 75-100 mg once daily (Guyatt, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      PCI:",
"     </b>",
"     Oral: Preprocedure: 81-325 mg (325 mg [nonenteric coated] in aspirin-naive patients) starting at least 2 hours (preferably 24 hours) before procedure. Postprocedure: 81 mg once daily continued indefinitely (in combination with a P2Y",
"     <sub>",
"      12",
"     </sub>",
"     inhibitor [eg, clopidogrel, prasugrel, ticagrelor] up to 12 months) (Levine, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternatively, in patients who have undergone elective PCI with either bare metal or drug-eluting stent placement:",
"     </i>",
"     The American College of Chest Physicians recommends the use of 75-325 mg once daily (in combination with clopidogrel) for 1 month (BMS) or 3-6 months (dependent upon DES type) followed by 75-100 mg once daily (in combination with clopidogrel) for up to12 months. For patients who underwent PCI but did not have stent placement, 75-325 mg once daily (in combination with clopidogrel) for 1 month is recommended. In either case, single antiplatelet therapy (either aspirin or clopidogrel) is recommended indefinitely (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pericarditis associated with myocardial infarction (unlabeled use):",
"     </b>",
"     Oral: 162-325 mg once daily; doses as high as 650 mg every 4-6 hours may be required; enteric-coated recommended (Antman, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Peripheral arterial disease (unlabeled use):",
"     </b>",
"     Oral: 75-100 mg once daily (Guyatt, 2012)",
"     <b>",
"      or",
"     </b>",
"     75-325 mg once daily; may use in conjunction with clopidogrel in those who are not at an increased risk of bleeding but are of high cardiovascular risk.",
"     <b>",
"      Note:",
"     </b>",
"     These recommendations also pertain to those with intermittent claudication or critical limb ischemia, prior lower extremity revascularization, or prior amputation for lower extremity ischemia (Rooke, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Peripheral artery percutaneous transluminal angioplasty (with or without stenting) or peripheral artery bypass graft surgery, postprocedure (unlabeled use):",
"     </b>",
"     Oral: 75-100 mg once daily (Guyatt, 2012).",
"     <b>",
"      Note:",
"     </b>",
"     For below-knee bypass graft surgery with prosthetic grafts, combine with clopidogrel (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pre-eclampsia prevention (women at risk) (unlabeled use):",
"     </b>",
"     Oral: 75-100 mg once daily starting in the second trimester (Guyatt, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Primary prevention:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      American College of Cardiology/American Heart Association:",
"     </i>",
"     Prevention of myocardial infarction: 75-162 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Patients are most likely to benefit if their 10-year coronary heart disease risk is &ge;6% (Antman, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      American College of Chest Physicians:",
"     </i>",
"     Prevention of myocardial infarction and stroke: Select individuals &ge;50 years of age (without symptomatic cardiovascular disease): 75-100 mg once daily (Guyatt, 2012; Grade 2B, weak recommendation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prosthetic heart valve:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Bioprosthetic aortic valve (patient in normal sinus rhythm) (unlabeled use):",
"     </i>",
"     50-100 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     If mitral bioprosthetic valve, oral anticoagulation with warfarin (instead of aspirin) is recommended for the first 3 months postoperatively, followed by aspirin alone (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Mechanical aortic or mitral valve (unlabeled use):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Low risk of bleeding: 50-100 mg once daily (in combination with warfarin) (Guyatt, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     History of thromboembolism while receiving oral anticoagulants: 75-100 mg once daily (in combination with warfarin) (Furie, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Transcatheter aortic bioprosthetic valve (unlabeled use):",
"     </i>",
"     50-100 mg once daily (in combination with clopidogrel) (Guyatt, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stroke/TIA:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Acute ischemic stroke/TIA:",
"     </i>",
"     Initial: 160-325 mg within 48 hours of stroke/TIA onset, followed by 75-100 mg once daily (Adams, 2007; Guyatt, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cardioembolic, secondary prevention (oral anticoagulation unsuitable):",
"     </i>",
"     75-100 mg once daily (in combination with clopidogrel) (Guyatt, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cryptogenic with patent foramen ovale (PFO) or atrial septal aneurysm:",
"     </i>",
"     50-100 mg once daily (Guyatt, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Noncardioembolic, secondary prevention:",
"     </i>",
"     75-325 mg once daily (Smith, 2011)",
"     <b>",
"      or",
"     </b>",
"     75-100 mg once daily (Guyatt, 2012).",
"     <b>",
"      Note:",
"     </b>",
"     Combination aspirin/extended release dipyridamole or clopidogrel is preferred over aspirin alone (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Women at high risk, primary prevention:",
"     </i>",
"     81 mg once daily",
"     <b>",
"      or",
"     </b>",
"     100 mg every other day (Goldstein, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F137119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"      see \"Aspirin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Analgesic and antipyretic:",
"     </b>",
"     Oral, rectal: 10-15 mg/kg/dose every 4-6 hours, up to a total of 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anti-inflammatory:",
"     </b>",
"     Oral: Initial: 60-90 mg/kg/day in divided doses; usual maintenance: 80-100 mg/kg/day divided every 6-8 hours; monitor serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiplatelet effects:",
"     </b>",
"     Adequate pediatric studies have not been performed; pediatric dosage is derived from adult studies and clinical experience and is not well established. Doses are typically rounded to a convenient amount (eg,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of 81 mg tablet).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Acute ischemic stroke (AIS):",
"     </i>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Noncardioembolic: 1-5 mg/kg/dose once daily for &ge;2 years; patients with recurrent AIS or TIAs should be transitioned to clopidogrel, LMWH, or warfarin (Monagle, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Secondary to Moyamoya and non-Moyamoya vasculopathy: 1-5 mg/kg/dose once daily.",
"     <b>",
"      Note:",
"     </b>",
"     In non-Moyamoya vasculopathy, continue aspirin for 3 months, with subsequent use guided by repeat cerebrovascular imaging (Monagle, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Blalock-Taussig shunts, primary prophylaxis (unlabeled use):",
"     </i>",
"     Oral: 1-5 mg/kg/dose once daily (Monagle, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Fontan surgery, primary prophylaxis:",
"     </i>",
"     Oral: 5 mg/kg/dose once daily (Monagle, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prosthetic heart valve:",
"     </i>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bioprosthetic aortic valve (in normal sinus rhythm): 1-5 mg/kg/dose once daily (Monagle, 2012; Guyatt, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mechanical aortic and/or mitral valve: Low-dose aspirin (eg, 1-5 mg/kg/day) combined with vitamin K antagonist (eg, warfarin) is recommended as first-line antithrombotic therapy (Guyatt, 2012). Alternative regimens: 6-20 mg/kg/dose once daily in combination with dipyridamole (Bradley, 1985; El Makhlouf, 1987; LeBlanc, 1993; Serra, 1987; Solymar, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Ventricular assist device (VAD) placement:",
"     </i>",
"     1-5 mg/kg/dose once daily initiated within 72 hours of VAD placement; should be used with heparin (initiated between 8-48 hours following implantation) (Monagle, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kawasaki disease (unlabeled use):",
"     </b>",
"     Oral: 80-100 mg/kg/day divided every 6 hours for up to 14 days (until fever resolves for at least 48 hours); then decrease dose to 3-5 mg/kg/day once daily; in patients without coronary artery abnormalities, give lower dose (ie, 3-5 mg/kg/day) for at least 6-8 weeks. In patients with coronary artery abnormalities, low-dose aspirin should be continued indefinitely (in combination with warfarin).",
"     <b>",
"      Note:",
"     </b>",
"     Combine with I.V. immune globulin treatment within 10 days of symptom onset (Newbuger, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F137099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F137100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialyzable (50% to 100%)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F137101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in severe liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F137065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bayer&reg; Aspirin Extra Strength: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bayer&reg; Genuine Aspirin: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bayer&reg; Women's Low Dose Aspirin: 81 mg [contains elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral [buffered]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ascriptin&reg; Maximum Strength: 500 mg [contains aluminum hydroxide, calcium carbonate, magnesium hydroxide]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bayer&reg; Plus Extra Strength: 500 mg [contains calcium carbonate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, enteric coated, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bayer&reg; Aspirin Regimen Regular Strength: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gum, chewing, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aspergum&reg;: 227 mg (12s) [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aspergum&reg;: 227 mg (12s) [orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal: 300 mg (12s); 600 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aspercin: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aspirtab: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bayer&reg; Genuine Aspirin: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [buffered]: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ascriptin&reg; Regular Strength: 325 mg [contains aluminum hydroxide, calcium carbonate, magnesium hydroxide]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buffasal: 325 mg [contains magnesium oxide]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bufferin&reg;: 325 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bufferin&reg; Extra Strength: 500 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buffinol: 324 mg [sugar free; contains magnesium oxide]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tri-Buffered Aspirin: 325 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral: 81 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bayer&reg; Aspirin Regimen Children's: 81 mg [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bayer&reg; Aspirin Regimen Children's: 81 mg [orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     St Joseph&reg; Adult Aspirin: 81 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, enteric coated, oral: 81 mg, 325 mg, 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aspir-low: 81 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bayer&reg; Aspirin Regimen Adult Low Strength: 81 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ecotrin&reg;: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ecotrin&reg; Arthritis Strength: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ecotrin&reg; Low Strength: 81 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Halfprin&reg;: 81 mg, 162 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     St Joseph&reg; Adult Aspirin: 81 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F137050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes gum",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F137069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not crush enteric coated tablet. Administer with food or a full glass of water to minimize GI distress. For acute myocardial infarction, have patient chew tablet.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F137068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild-to-moderate pain, inflammation, and fever; prevention and treatment of acute coronary syndromes (ST-elevation MI, non-ST-elevation MI, unstable angina), acute ischemic stroke, and transient ischemic episodes; management of rheumatoid arthritis, rheumatic fever, osteoarthritis; adjunctive therapy in revascularization procedures (coronary artery bypass graft [CABG], percutaneous transluminal coronary angioplasty [PTCA], carotid endarterectomy), stent implantation",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F137141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low doses have been used in the prevention of pre-eclampsia, complications associated with autoimmune disorders such as lupus or antiphospholipid syndrome; colorectal cancer; Kawasaki disease; alternative therapy for prevention of thromboembolism associated with atrial fibrillation in patients not candidates for warfarin; pericarditis associated with MI; thromboprophylaxis for aortic valve repair, Blalock-Taussig shunt placement, carotid artery stenosis, coronary artery disease, Fontan surgery, peripheral arterial occlusive disease, peripheral artery percutaneous transluminal angioplasty, peripheral artery bypass graft surgery, prosthetic valves, ventricular assist device (VAD) placement",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F137154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Aspirin may be confused with Afrin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ascriptin&reg; may be confused with Aricept&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ecotrin&reg; may be confused with Edecrin&reg;, Epogen&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Halfprin&reg; may be confused with Haltran&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ZORprin&reg; may be confused with Zyloprim&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cartia [multiple international markets] may be confused with Cartia XT brand name for diltiazem [U.S.]",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F137143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As with all drugs which may affect hemostasis, bleeding is associated with aspirin. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables including dosage, concurrent use of multiple agents which alter hemostasis, and patient susceptibility. Many adverse effects of aspirin are dose related, and are extremely rare at low dosages. Other serious reactions are idiosyncratic, related to allergy or individual sensitivity. Accurate estimation of frequencies is not possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Cardiovascular: Hypotension, tachycardia, dysrhythmias, edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Fatigue, insomnia, nervousness, agitation, confusion, dizziness, headache, lethargy, cerebral edema, hyperthermia, coma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, angioedema, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, hyperkalemia, dehydration, hypoglycemia (children), hyperglycemia, hypernatremia (buffered forms)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting, dyspepsia, epigastric discomfort, heartburn, stomach pain, gastrointestinal ulceration (6% to 31%), gastric erosions, gastric erythema, duodenal ulcers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, disseminated intravascular coagulation (DIC), prothrombin times prolonged, coagulopathy, thrombocytopenia, hemolytic anemia, bleeding, iron-deficiency anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity, transaminases increased, hepatitis (reversible)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Rhabdomyolysis, weakness, acetabular bone destruction (OA)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing loss, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Interstitial nephritis, papillary necrosis, proteinuria, renal failure (including cases caused by rhabdomyolysis), BUN increased, serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, bronchospasm, dyspnea, laryngeal edema, hyperpnea, tachypnea, respiratory alkalosis, noncardiogenic pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, prolonged pregnancy and labor, stillbirths, low birth weight, peripartum bleeding, Reye's syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Colonic ulceration, esophageal stricture, esophagitis with esophageal ulcer, esophageal hematoma, oral mucosal ulcers (aspirin-containing chewing gum), coronary artery spasm, conduction defect and atrial fibrillation (toxicity), delirium, ischemic brain infarction, colitis, rectal stenosis (suppository), cholestatic jaundice, periorbital edema, rhinosinusitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F137072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to salicylates, other NSAIDs, or any component of the formulation; asthma; rhinitis; nasal polyps; inherited or acquired bleeding disorders (including factor VII and factor IX deficiency); do not use in children (&lt;16 years of age) for viral infections (chickenpox or flu symptoms), with or without fever, due to a potential association with Reye's syndrome",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F137054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Salicylate sensitivity: Patients with sensitivity to tartrazine dyes, nasal polyps, and asthma may have an increased risk of salicylate sensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tinnitus: Discontinue use if tinnitus or impaired hearing occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Upper gastrointestinal (UGI) events (eg, symptomatic or complicated ulcers): Low-dose aspirin for cardioprotective effects is associated with a two- to fourfold increase in UGI events. The risks of these events increase with increasing aspirin dose; during the chronic phase of aspirin dosing, doses &gt;81 mg are not recommended unless indicated (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with platelet and bleeding disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dehydration: Use with caution in patients with dehydration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Heavy ethanol use (&gt;3 drinks/day) can increase bleeding risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with erosive gastritis or peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Avoid use in severe hepatic failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with mild-to-moderate renal impairment (only at high dosages); avoid in severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alteplase: In the treatment of acute ischemic stroke, avoid aspirin for 24 hours following administration of alteplase; administration within 24 hours increases the risk of hemorrhagic transformation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspirin: Concurrent use of aspirin and clopidogrel is not recommended for secondary prevention of ischemic stroke or TIA in patients unable to take oral anticoagulants due to hemorrhagic risk (Furie, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; COX-2 inhibitors/NSAIDs: When used concomitantly with &le;325 mg of aspirin, NSAIDs (including selective COX-2 inhibitors) substantially increase the risk of gastrointestinal complications (eg, ulcer); concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid chronic use of doses &gt;325 mg/day (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent); nonselective oral NSAID use is associated with an increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, &gt;75 years or age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents) (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: When used for self-medication (OTC labeling): Children and teenagers who have or are recovering from chickenpox or flu-like symptoms should not use this product. Changes in behavior (along with nausea and vomiting) may be an early sign of Reye's syndrome; patients should be instructed to contact their healthcare provider if these occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: In general, low doses during pregnancy needed for the treatment of certain medical conditions have not been shown to cause fetal harm; however, discontinuing therapy prior to delivery is recommended. Use of safer agents for routine management of pain or headache throughout pregnancy should be considered. If possible, avoid use during the third trimester of pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: ASA should be avoided (if possible) in surgical patients for 1-2 weeks prior to surgery, to reduce the risk of excessive bleeding (except in patients with cardiac stents that have not completed their full course of dual antiplatelet therapy [aspirin, clopidogrel]; patient specific situations need to be discussed with cardiologist; AHA/ACC/SCAI/ACS/ADA Science Advisory provides recommendations).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F137138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Salicylates may diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alendronate: Aspirin may enhance the adverse/toxic effect of Alendronate. Specifically gastrointestinal adverse events.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the anticoagulant effect of Salicylates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Salicylates may increase the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Salicylates may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Weigh potential benefits of drotrecogin against increased bleeding risk in patients who have received  platelet inhibitors including aspirin (over 650 mg daily within 1 week). Monitor for bleeding and stop infusion if clinically important bleeding occurs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Floctafenine may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: Aspirin may enhance the anticoagulant effect of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Salicylates may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, aspirin may decrease absorption of ascorbic acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Aspirin may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).  Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended.  While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissable, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Aspirin may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of aspirin with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Acid Phosphate: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: Salicylates may diminish the therapeutic effect of Probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of other Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: Aspirin may enhance the antiplatelet effect of Ticagrelor. Aspirin may diminish the therapeutic effect of Ticagrelor. More specifically, the benefits of ticagrelor relative to clopidogrel may be diminished in patients receiving daily aspirin doses greater than 100-150 mg daily.  Management: Avoid daily aspirin doses greater than 100 mg in patients receiving ticagrelor.  Canadian recommendations are to avoid daily aspirin doses greater than 150 mg.  Daily low-dose aspirin (U.S.: 75-100 mg; Canada: 75-150 mg) is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiludronate: Aspirin may decrease the serum concentration of Tiludronate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Salicylates may increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F137088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal damage).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food may decrease the rate but not the extent of oral absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Folic acid: Hyperexcretion of folate; folic acid deficiency may result, leading to macrocytic anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iron: With chronic aspirin use and at doses of 3-4 g/day, iron-deficiency anemia may result.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sodium: Hypernatremia resulting from buffered aspirin solutions or sodium salicylate containing high sodium content. Avoid or use with caution in CHF or any condition where hypernatremia would be detrimental.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benedictine liqueur, prunes, raisins, tea, and gherkins: Potential salicylate accumulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fresh fruits containing vitamin C: Displace drug from binding sites, resulting in increased urinary excretion of aspirin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid cat's claw, dong quai, evening primrose, feverfew, garlic, ginger, ginkgo, red clover, horse chestnut, green tea, ginseng (all have additional antiplatelet activity). Limit curry powder, paprika, licorice; may cause salicylate accumulation. These foods contain 6 mg salicylate/100 g. An ordinary American diet contains 10-200 mg/day of salicylate.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F137075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Salicylates have been noted to cross the placenta and enter fetal circulation. Adverse effects reported in the fetus include mortality, intrauterine growth retardation, salicylate intoxication, bleeding abnormalities, and neonatal acidosis. Use of aspirin close to delivery may cause premature closure of the ductus arteriosus. Adverse effects reported in the mother include anemia, hemorrhage, prolonged gestation, and prolonged labor (&Oslash;stensen, 1998). Aspirin has been used for the prevention of pre-eclampsia; however, the ACOG currently recommends that it not be used in low-risk women (ACOG, 2002). Low-dose aspirin is used to treat complications resulting from antiphospholipid syndrome in pregnancy (either primary or secondary to SLE) (Carp, 2004; Guyatt, 2012; Tincani, 2003). In general, low doses during pregnancy needed for the treatment of certain medical conditions have not been shown to cause fetal harm, however, discontinuing therapy prior to delivery is recommended (&Oslash;stensen, 2006). Use of safer agents for routine management of pain or headache should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F137104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk (AAP recommends use &ldquo;with caution&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F137076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low amounts of aspirin can be found in breast milk. Milk/plasma ratios ranging from 0.03-0.3 have been reported. Peak levels in breast milk are reported to be at ~9 hours after a dose. Metabolic acidosis was reported in one infant following an aspirin dose of 3.9 g/day in the mother.  The WHO considers occasional doses of aspirin to be compatible with breast-feeding, but to avoid long-term therapy and consider monitoring the infant for adverse effects (WHO, 2002). Other sources suggest avoiding aspirin while breast-feeding due to the theoretical risk of Reye's syndrome (Bar-Oz, 2003; Spigset, 2000). When used for vascular indications, breast-feeding may be continued during low-dose aspirin therapy (Guyatt, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F137077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food or large volume of water or milk to minimize GI upset.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F137074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Aspirin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81 mg (36): $1.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Bayer Low Dose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81 mg (36): $2.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (St Joseph Adult Low Dose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (36): $1.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (St Joseph Adult Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (36): $1.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (St Joseph Aspirin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81 mg (36): $2.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Stanback Headache Powders Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     650-200-32 mg (6): $1.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Aspirin Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $11.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $11.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $12.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (12): $1.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (12): $1.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Aspir-Low Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81 mg (250): $6.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Aspirin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81 mg (120): $2.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (60): $2.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Bayer Aspirin EC Low Dose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81 mg (400): $13.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Bayer Aspirin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (200): $10.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Bayer Aspirin Regimen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (100): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Bayer Low Dose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81 mg (120): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Ecotrin Low Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81 mg (150): $6.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Ecotrin Maximum Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (75): $6.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Ecotrin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (125): $6.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (EcPirin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (1000): $17.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Halfprin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81 mg (90): $5.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     162 mg (60): $3.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Miniprin Low Dose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81 mg (120): $3.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (St Joseph Aspirin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81 mg (100): $5.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ascriptin MS Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-33-33-237 mg (85): $10.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ascriptin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (100): $7.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Aspirin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81 mg (100): $1.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (100): $2.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bayer Advanced Aspirin Ex St Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (40): $5.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bayer Advanced Aspirin Reg St Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (24): $3.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bayer Aspirin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (50): $4.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bayer Plus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (50): $5.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bayer Womens Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81-300 mg (60): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bufferin Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (65): $6.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bufferin Low Dose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81 mg (130): $5.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bufferin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (65): $4.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cope Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400-32 mg (60): $12.60",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F137066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Timing of serum samples: Peak levels usually occur 2 hours after ingestion. Salicylate serum concentrations correlate with the pharmacological actions and adverse effects observed. The serum salicylate concentration (mcg/mL) and the corresponding clinical correlations are as follows: See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Serum Salicylate: Clinical Correlations",
"     </caption>",
"     <col align=\"center\" width=\"115\">",
"     </col>",
"     <col align=\"left\" width=\"120\">",
"     </col>",
"     <col align=\"left\" width=\"245\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Serum Salicylate Concentration",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mcg/mL)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Desired Effects",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Adverse Effects / Intoxication",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         ~100",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Antiplatelet",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Antipyresis",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Analgesia",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         GI intolerance and bleeding, hypersensitivity, hemostatic defects",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150-300",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Anti-inflammatory",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Mild salicylism",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250-400",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Treatment of rheumatic fever",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Nausea/vomiting, hyperventilation, salicylism, flushing, sweating, thirst, headache, diarrhea, and tachycardia",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;400-500",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Respiratory alkalosis, hemorrhage, excitement, confusion, asterixis, pulmonary edema, convulsions, tetany, metabolic acidosis, fever, coma, cardiovascular collapse, renal and respiratory failure",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F137078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      AAS (AR, BR, ES);",
"     </li>",
"     <li>",
"      Acard (PL);",
"     </li>",
"     <li>",
"      Aceprin (MY);",
"     </li>",
"     <li>",
"      Acetard (FI);",
"     </li>",
"     <li>",
"      Aceticil (BR);",
"     </li>",
"     <li>",
"      Acetysal (BG);",
"     </li>",
"     <li>",
"      Adiro (MX, VE);",
"     </li>",
"     <li>",
"      Albyl-E (NO);",
"     </li>",
"     <li>",
"      Alka-Seltzer (AU);",
"     </li>",
"     <li>",
"      Ansin (TW);",
"     </li>",
"     <li>",
"      Antacsal-E (MX);",
"     </li>",
"     <li>",
"      Anthrom (PH);",
"     </li>",
"     <li>",
"      Aptor (ID);",
"     </li>",
"     <li>",
"      Asapor (FI);",
"     </li>",
"     <li>",
"      Asawin (CO);",
"     </li>",
"     <li>",
"      Ascardia (ID);",
"     </li>",
"     <li>",
"      Aspa (TW);",
"     </li>",
"     <li>",
"      Aspec (NZ);",
"     </li>",
"     <li>",
"      Aspen (PH);",
"     </li>",
"     <li>",
"      Aspent (TH);",
"     </li>",
"     <li>",
"      Aspex (IL);",
"     </li>",
"     <li>",
"      Aspilets (ID, PH);",
"     </li>",
"     <li>",
"      Aspilets EC (PH);",
"     </li>",
"     <li>",
"      Aspire (TW);",
"     </li>",
"     <li>",
"      Aspirem (BB, BM, BS, BZ, GY, JM, PR, SR, TT);",
"     </li>",
"     <li>",
"      Aspirin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, HK, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Aspirin Bayer (HK);",
"     </li>",
"     <li>",
"      Aspirin Cardio (IL, SG);",
"     </li>",
"     <li>",
"      Aspirina (CN, CO, EC);",
"     </li>",
"     <li>",
"      Aspirina efervescente (MX);",
"     </li>",
"     <li>",
"      Aspirina Junior (MX);",
"     </li>",
"     <li>",
"      Aspro (AT, AU, CH, CZ, FR, GB, IT, NL, NZ);",
"     </li>",
"     <li>",
"      Asprovit (EE);",
"     </li>",
"     <li>",
"      Asrina (TH);",
"     </li>",
"     <li>",
"      ASS (DE);",
"     </li>",
"     <li>",
"      Asta (PY);",
"     </li>",
"     <li>",
"      Asthromed (PH);",
"     </li>",
"     <li>",
"      Astrix (KP, PH);",
"     </li>",
"     <li>",
"      B-Aspirin (TH);",
"     </li>",
"     <li>",
"      Bamyl (SE);",
"     </li>",
"     <li>",
"      Bayaspirin Protect 100 (CL);",
"     </li>",
"     <li>",
"      Bayaspirina (AR);",
"     </li>",
"     <li>",
"      Bayer Aspirin Cardio (ZA);",
"     </li>",
"     <li>",
"      Bayprin EC (PH);",
"     </li>",
"     <li>",
"      Bokey (SG, TW);",
"     </li>",
"     <li>",
"      Bufferin (UY);",
"     </li>",
"     <li>",
"      Caprin (GB);",
"     </li>",
"     <li>",
"      Cardioaspirina (CO, PE);",
"     </li>",
"     <li>",
"      Cardioprin (TW);",
"     </li>",
"     <li>",
"      Cardioprin 100 (IL);",
"     </li>",
"     <li>",
"      Cardioton (PE);",
"     </li>",
"     <li>",
"      Cardiprin (AU, HK);",
"     </li>",
"     <li>",
"      Carnyl (DK);",
"     </li>",
"     <li>",
"      Cartia (AU, PT);",
"     </li>",
"     <li>",
"      Caspirin (MY);",
"     </li>",
"     <li>",
"      Circlevein (KP);",
"     </li>",
"     <li>",
"      Colfarit (CZ, HN);",
"     </li>",
"     <li>",
"      Comoprin (TH);",
"     </li>",
"     <li>",
"      Cortal (PH);",
"     </li>",
"     <li>",
"      Dispril (AE, BE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, NO, OM, QA, SA, SY, TR, YE);",
"     </li>",
"     <li>",
"      Disprin (AU, BB, BF, BJ, BM, BS, BZ, CI, ET, GB, GH, GM, GN, GY, HK, IE, IN, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, NZ, PK, PR, SC, SD, SG, SL, SN, SR, TN, TT, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Ecasil (BR);",
"     </li>",
"     <li>",
"      Ecotrin (AR, CN, MX, NZ, TW);",
"     </li>",
"     <li>",
"      Encine EM (TW);",
"     </li>",
"     <li>",
"      Eskotrin (VE);",
"     </li>",
"     <li>",
"      Frosit (ID);",
"     </li>",
"     <li>",
"      Globentyl (DK);",
"     </li>",
"     <li>",
"      Glocar (ID);",
"     </li>",
"     <li>",
"      Godamed (IL);",
"     </li>",
"     <li>",
"      Idotyl (DK);",
"     </li>",
"     <li>",
"      Lopirin (TW);",
"     </li>",
"     <li>",
"      Magnecyl (SE);",
"     </li>",
"     <li>",
"      Melabon (DE);",
"     </li>",
"     <li>",
"      Miniaspi 80 (ID);",
"     </li>",
"     <li>",
"      Naspro (ID);",
"     </li>",
"     <li>",
"      Nu-Seals (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Plaquetasa (CR, GT, SV);",
"     </li>",
"     <li>",
"      Plewin (CN);",
"     </li>",
"     <li>",
"      Proprin (GB);",
"     </li>",
"     <li>",
"      Rhonal (VE);",
"     </li>",
"     <li>",
"      Salisalido (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Salospir (GR);",
"     </li>",
"     <li>",
"      Sedergine (BE);",
"     </li>",
"     <li>",
"      Solprin (AU);",
"     </li>",
"     <li>",
"      Tevapirin (IL);",
"     </li>",
"     <li>",
"      Thrombo-Aspilets (ID);",
"     </li>",
"     <li>",
"      Thrombo-ASS (EE);",
"     </li>",
"     <li>",
"      Tromcor (PH);",
"     </li>",
"     <li>",
"      V-AS (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F137053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Irreversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, via acetylation, which results in decreased formation of prostaglandin precursors; irreversibly inhibits formation of prostaglandin derivative, thromboxane A",
"     <sub>",
"      2",
"     </sub>",
"     , via acetylation of platelet cyclooxygenase, thus inhibiting platelet aggregation; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F137071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 10 L; readily into most body fluids and tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hydrolyzed to salicylate (active) by esterases in GI mucosa, red blood cells, synovial fluid, and blood; metabolism of salicylate occurs primarily by hepatic conjugation; metabolic pathways are saturable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 50% to 75% reaches systemic circulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Parent drug: 15-20 minutes; Salicylates (dose dependent): 3 hours at lower doses (300-600 mg), 5-6 hours (after 1 g), 10 hours with higher doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (75% as salicyluric acid, 10% as salicylic acid)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Obstetric Practice, &ldquo;ACOG Practice Bulletin. Diagnosis and Management of Preeclampsia and Eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists,&rdquo;",
"      <i>",
"       Int J Gynaecol Obstet",
"      </i>",
"      , 2002, 77(1):67-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/12094777/pubmed\" id=\"12094777\" target=\"_blank\">",
"        12094777",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Adams JA, Albers G, Alberts JS, et al, &ldquo;Update to the AHA/ASA Recommendations for the Prevention of Stroke on Patients With Stroke and Transient Ischemic Attack,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2008, 39(5):1647-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/18322260/pubmed\" id=\"18322260\" target=\"_blank\">",
"        18322260",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Adams HP, del Zoppo G, Alberts MJ, et al, &ldquo;Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2007, 38(5):1655-1711.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/17431204/pubmed\" id=\"17431204\" target=\"_blank\">",
"        17431204",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(7):e148-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/17679616/pubmed\" id=\"17679616\" target=\"_blank\">",
"        17679616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(9):e82-292.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/15339869/pubmed\" id=\"15339869\" target=\"_blank\">",
"        15339869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bar-Oz B, Bulkowstein M, Benyamini L, et al, &ldquo;Use of Antibiotic and Analgesic Drugs During Lactation,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2003, 26(13):925-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/14583068/pubmed\" id=\"14583068\" target=\"_blank\">",
"        14583068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bates ER, Babb JD, Casey DE Jr, et al, &ldquo;ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (ACF/SCAI/SVMB/SIR/ASITN Clinical Expert Consensus Document Committee on Carotid Stenting),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 49(1):126-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/17207736/pubmed\" id=\"17207736\" target=\"_blank\">",
"        17207736",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Branch DW and Khamashta MA, &ldquo;Antiphospholipid Syndrome: Obstetric Diagnosis, Management, and Controversies,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2003, 101(6):1333-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/12798544/pubmed\" id=\"12798544\" target=\"_blank\">",
"        12798544",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Braunwald E, Antman EM, Beasley JW, et al, &ldquo;ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2002, 40(7):1366-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/12383588/pubmed\" id=\"12383588\" target=\"_blank\">",
"        12383588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Calonge N, Petitti DB, DeWitt TG, et al, &ldquo;Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement. U.S Preventive Services Task Force,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2009, 150(6):396-404.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/19293072/pubmed\" id=\"19293072\" target=\"_blank\">",
"        19293072",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al,  &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carp HJ, &ldquo;Antiphospholipid Syndrome in Pregnancy,&rdquo;",
"      <i>",
"       Curr Opin Obstet Gynecol",
"      </i>",
"      , 2004, 16(2):129-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/15017341/pubmed\" id=\"15017341\" target=\"_blank\">",
"        15017341",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"CLASP: A Randomised Trial of Low-Dose Aspirin for the Prevention and Treatment of Pre-eclampsia Among 9364 Pregnant Women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1994, 343(8898):619-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/7906809/pubmed\" id=\"7906809\" target=\"_blank\">",
"        7906809",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coomarasamy A, Honest H, Papaioannou S, et al, &ldquo;Aspirin for Prevention of Preeclampsia in Women With Historical Risk Factors: A Systematic Review,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2003, 101(6):1319-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/12798543/pubmed\" id=\"12798543\" target=\"_blank\">",
"        12798543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cryer B, Verlin RG, Cooper SA, et al, &ldquo;Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Ibuprofen Effects on Thromboxane B2 Concentrations in Aspirin-Treated Healthy Adult Volunteers,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2005, 27(2):185-191.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/15811481/pubmed\" id=\"15811481\" target=\"_blank\">",
"        15811481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Department of Health and Human Services, Food and Drug Administration, &ldquo;Labeling for Oral and Rectal Over-the-Counter Drug Products Containing Aspirin and Nonaspirin Salicylates; Reye's Syndrome Warning; Final Rule, (29 CFR Part 201),&rdquo;",
"      <i>",
"       Fed Regist",
"      </i>",
"      , April 17, 2003, 18861-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/10177739/pubmed\" id=\"10177739\" target=\"_blank\">",
"        10177739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furie KL, Kasner SE, Adams RJ, et al, &ldquo;Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2011,42(1):227-76",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/20966421/pubmed\" id=\"20966421\" target=\"_blank\">",
"        20966421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldstein LB, Bushnell CD, Adams RJ, et al, \"Guidelines for the Primary Prevention of Stroke: A  Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,\"",
"      <i>",
"       Stroke",
"      </i>",
"      ,  2011, 42(2):517-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/21127304/pubmed\" id=\"21127304\" target=\"_blank\">",
"        21127304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grines CL, Bonow RO, Casey DE, et al, &ldquo;AHA/ACC/SCAI/ACS/ADA Science Advisory, Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents. A Science Advisory From the American Heart Association, American College of Cardiology, Society of Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association With Representation from the Amercian College of Physicians,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115(6):813-8. Available at  file://circ.ahajournals.org/cgi/content/full/115/6/813",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/17224480/pubmed\" id=\"17224480\" target=\"_blank\">",
"        17224480",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gum PA, Kottke-Marchant K, Welsh PA, et al,&ldquo;A Prospective, Blinded Determination of the Natural History of Aspirin Resistance Among Stable Patients With Cardiovascular Disease,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2003, 41(6):961-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/12651041/pubmed\" id=\"12651041\" target=\"_blank\">",
"        12651041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al, &ldquo;ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). A Collaborative Report of the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2006, 113(11):e463-654.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/16549646/pubmed\" id=\"16549646\" target=\"_blank\">",
"        16549646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin CP and Talbert RL,&ldquo;Aspirin Resistance: An Evaluation of Current Evidence and Measurement Methods,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2005, 25(7):942-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/16006273/pubmed\" id=\"16006273\" target=\"_blank\">",
"        16006273",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Medeiros FB, de Andrade AC, Angelis GA, et al, \"Bleeding Evaluation During Single Tooth Extraction in Patients With Coronary Artery Disease and Acetylsalicylic Acid Therapy Suspension: A Prospective, Double-Blinded, and Randomized Study,\"",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2011, 69(12):2949-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/21802823/pubmed\" id=\"21802823\" target=\"_blank\">",
"        21802823",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Chan A, Goldenberg NA, et al, \"Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition),\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e737-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/22315277/pubmed\" id=\"22315277\" target=\"_blank\">",
"        22315277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Cochrane A, Roberts R, et al, &ldquo;A Multicenter, Randomized Trial Comparing Heparin/Warfarin and Acetylsalicylic Acid as Primary Thromboprophylaxis for 2 Years after the Fontan Procedure in Children,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2011, 58(6):645-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/21798429/pubmed\" id=\"21798429\" target=\"_blank\">",
"        21798429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &Oslash;stensen M, Khamashta M, Lockshin M, \"Anti-inflammatory and Immunosuppressive Drugs and Reproduction,\"",
"      <i>",
"       Arthritis Res Ther",
"      </i>",
"      , 2006, 8(3):209.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/16712713/pubmed\" id=\"16712713\" target=\"_blank\">",
"        16712713",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &Oslash;stensen M, &ldquo;Nonsteroidal Anti-inflammatory Drugs During Pregnancy,&rdquo;",
"      <i>",
"       Scand J Rheumatol Suppl",
"      </i>",
"      , 1998, 107:128-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/9759151/pubmed\" id=\"9759151\" target=\"_blank\">",
"        9759151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Physician's Health Study: Aspirin and Primary Prevention of Coronary Heart Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1989, 321(26):1825-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/2594041/pubmed\" id=\"2594041\" target=\"_blank\">",
"        2594041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pignone M, Alberts MJ, Colwell JA, et al, &ldquo;Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes: A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 121(24):2694-2701. Available at  file://circ.ahajournals.org/cgi/reprint/121/24/2694.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/20508178/pubmed\" id=\"20508178\" target=\"_blank\">",
"        20508178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ridker PM, Cook NR, Lee IM, et al, \"A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(13):1293-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/15753114/pubmed\" id=\"15753114\" target=\"_blank\">",
"        15753114",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rooke TW, Hirsch AT, Misra S, et al, &ldquo;2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(18):2020-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/21959305/pubmed\" id=\"21959305\" target=\"_blank\">",
"        21959305",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sacco RL, Adams R, Albers G, et al, &ldquo;Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology Affirms the Value of this Guideline,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2006, 37(2):577-617.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/16432246/pubmed\" id=\"16432246\" target=\"_blank\">",
"        16432246",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanderson S, Emery J, Baglin T, et al, \"Narrative Review: Aspirin Resistance and Its Clinical Implications,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2005, 142(5):370-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/15738456/pubmed\" id=\"15738456\" target=\"_blank\">",
"        15738456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&ouml;mig A, Neumann FJ, Kastrati A, et al, &ldquo;A Randomized Comparison of Antiplatelet and Anticoagulant Therapy After the Placement of Coronary-Artery Stents,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(17):1084-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/8598866/pubmed\" id=\"8598866\" target=\"_blank\">",
"        8598866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2012, 28(2):125-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/22433576/pubmed\" id=\"22433576\" target=\"_blank\">",
"        22433576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spigset O and Hagg S, &ldquo;Analgesics and Breast-Feeding: Safety Considerations,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2000, 2(3):223-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/10937472/pubmed\" id=\"10937472\" target=\"_blank\">",
"        10937472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tincani A, Branch W, Levy RA, et al, &ldquo;Treatment of Pregnant Patients With Antiphospholipid Syndrome,&rdquo;",
"      <i>",
"       Lupus",
"      </i>",
"      , 2003, 12(7):524-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/12892392/pubmed\" id=\"12892392\" target=\"_blank\">",
"        12892392",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Preventive Services Task Force.",
"      <i>",
"       Aspirin for the Prevention of Cardiovascular Disease: Clinical Summary",
"      </i>",
"      . AHRQ Publication No.09-05129-EF-3, March 2009. Agency for Healthcare Research and Quality, Rockville, MD.",
"      <a href=\"file://www.ahrq.gov/clinic/uspstf09/aspirincvd/aspcvdrs.htm\" target=\"_blank\">",
"       file://www.ahrq.gov/clinic/uspstf09/aspirincvd/aspcvdrs.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123 (1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/7/24698/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization (WHO), \"Breastfeeding and Maternal Medication, Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs,\" 2013. Available at file://www.who.int/maternal_child_adolescent/documents/55732/en/index.html",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8907 Version 55.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-239B17CE44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_7_24698=[""].join("\n");
var outline_f24_7_24698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137093\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137094\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137145\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137098\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137119\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137099\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137100\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137101\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137065\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137050\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137069\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137068\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137141\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137154\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137143\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137072\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137054\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137138\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137059\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137088\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137075\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137104\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137076\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137077\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137074\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137066\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137078\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137053\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137071\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8907\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8907|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=related_link\">",
"      Aspirin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=related_link\">",
"      Aspirin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_7_24699="Entecavir lamiv refractory II";
var content_f24_7_24699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected virologic, biochemical, and serologic endpoints at week 48, lamivudine refractory patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"30%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Entecavir 1 mg",
"        <br/>",
"        (n = 141)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lamivudine 100 mg",
"        <br/>",
"        (n = 145)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        HBV DNA*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Proportion undetectable (&lt;300 copies/mL)",
"       </td>",
"       <td class=\"sublist_other\">",
"        19%",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        1%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mean changes from baseline (log10 copies/mL)",
"       </td>",
"       <td class=\"sublist_other\">",
"        -5.11",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        -0.48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ALT normalization (&le;1 X ULN)",
"       </td>",
"       <td>",
"        61%",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        15%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HBeAg seroconversion",
"       </td>",
"       <td>",
"        8%",
"       </td>",
"       <td>",
"        3%",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"     <br/>",
"     * Roche COBAS Amplicor PCR assay (LLOQ = 300 copies/mL).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     p&lt;0.0001.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_7_24699=[""].join("\n");
var outline_f24_7_24699=null;
var title_f24_7_24700="DMD during anesthesia";
var content_f24_7_24700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of the American College of Chest Physicians (ACCP) consensus statement suggestions for the management of patients with Duchenne muscular dystrophy (DMD) during general anesthesia or procedural sedation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Consider use of a total intravenous anesthesia technique for induction and maintenance of general anesthesia (eg, propofol and short-acting opioids)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; The use of depolarizing muscle relaxants such as succinylcholine is absolutely contraindicated because of the risk of fatal reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Optimize the medical setting and personnel in attendance when patients with DMD undergo general anesthesia or procedural sedation, and have an intensive care unit available for postprocedure care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Options for providing respiratory support during maintenance of general anesthesia or procedural sedation for patients with DMD include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Endotracheal intubation, with use of noninvasive positive pressure ventilation (NPPV) to facilitate extubation for selected patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Laryngeal mask airway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Mechanical ventilation via a mouthpiece with leak-proof seal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Manual or mechanical ventilation (using conventional ventilators or bilevel positive pressure ventilators designed for noninvasive respiratory support) delivered via a full face mask or nasal mask interface",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Application of ventilation in the assisted or controlled modes should be considered for patients with DMD and a forced vital capacity (FVC) &lt;50 percent of predicted, and strongly considered for those with an FVC &lt;30 percent of predicted, during induction of and recovery from general anesthesia and throughout procedural sedation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Options for respiratory support during induction of and recovery from general anesthesia or procedural sedation include manual ventilation using a flow-inflated manual resuscitation bag (standard \"anesthesia bag\") with a full face or nasal mask interface, and mechanical support using a conventional or noninvasive positive pressure ventilator via a full face or nasal mask",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Intraoperatively, continuously monitor oxyhemoglobin saturation measured by pulse oximetry and, whenever possible, blood or end-tidal carbon dioxide levels",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Birnkrant, DJ, Panitch, HB, Benditt, JO, et al. American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Chest 2007; 132:1977.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_7_24700=[""].join("\n");
var outline_f24_7_24700=null;
var title_f24_7_24701="Long term outcome enalapril";
var content_f24_7_24701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enalapril delays mortality in heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 246px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier analysis of patients entered into the CONSENSUS trial shows long-term benefit of enalapril compared to placebo (p = 0.008); the risk reduction, averaged over the ten year follow-up, was 30 percent even though the final outcomes were not different.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Swedberg K, Kjekshus J, Snapinn S, for the CONSENSUS Investigators, Eur Heart J 1999; 20:136.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_7_24701=[""].join("\n");
var outline_f24_7_24701=null;
var title_f24_7_24702="Positive SAECG predicts outcomes with NSVT";
var content_f24_7_24702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    The signal averaged ECG predicts outcome in patients with nonsustained ventricular tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 304px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a trial of 1925 patients with coronaray artery disease, asymptomatic nonsustained ventricular tachycardia and left ventricular dysfunction, the signal averaged ECG (SAECG) predicted outcome, particularly in those with a left ventricular ejection fraction (LVEF) &lt;30 percent. The two- and five-year event rates for patients with filtered QRS duration &gt;114 ms were 17 and 36 percent, respectively, compared with 10 and 23 percent, respectively, with a QRS &le;114 ms (p = 0.0001). In patients with an LVEF &ge;30 percent, the two- and five-year event rates were 6 and 13 percent, respectively and 11 and 22 percent, respectively, for a QRS &le; or &gt;114 ms (p = 0.01).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Gomes JA, Cain ME, et al. Circulation 2001; 104:436.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_7_24702=[""].join("\n");
var outline_f24_7_24702=null;
var title_f24_7_24703="MRI clavicle osteolysis";
var content_f24_7_24703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of osteolysis of the clavicle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 342px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFWAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDx2W1QoCDweue1QvpJK5IwD045NPi1G3WUKHDMOoPSthZBcFHVgzDnI6CgDmZdGkCsQDx7VQksHXOV/SvRIkDwNuzvB6Y6mrUehQzQkDaZSNwVqAPKm0926Kc/ShdPcdRXpcmgGGNZBgksAQOwp+u6EsN4ssbK0bqAVHUGgDzIWTdMfpQ1k4z8hxXYrp7xmZJtoAOVHt61CkAaBiSWQHC5HJzQBxMlqVJqEoVPSu4u9LQEhtu8EAgds1l32jSJGZVUlM4JxQBzNFW7i1aMniqhUg0AFIBS0hoAKKKKAFFLTQaM0AO4opBSigBwzkUrD2po60En1oABwalBqLNKGNAElIQM0wNzS7hQA4U4CmZFLnigB+aTNJmgUAOFGeKSjNAAeaUUlFAD8ilFMzTs0AKaYacTTaAFFLTRSigBMUYpaBQAmKdSZpaAENFNY8UUAVkWRCThizd+9dZ4Qu3+0rC5XcWxzU97psR8h7YZVx196jsrOazvFmIXKkGgDqI7qSOV0YbpEY5BrXs76QOrOAVK4HtXMahd7rqO7jfO44cHtV2GQOu3kqO4PrQB2dvNbjbLkPJ1UDuac8SJIZmxLzz7n2rloZJYZkCfKo49eK17aVmjBLZCHH0J70AXLjR7C/ltym+KYn593Qmsi70loGlDc7ZcIQK1orjCCR1LgtgMOxp0t4GXCfN7GgDlZbYss/mhQ69W96ihgWa2Zd5fBGUFbF86SElVWM9HVu9ZZuooWBTlXz8y9jQBhXWmiWXYUKBs4JrndR0x4HII6V6AsQdQN5ZicgnoPrTdS0v7TGXIB9dvUUAeWOhU9KjPWuqutI3blwA+44+lYE9o6ZOOKAKdIaeykUygAFLSCloAKUUmaBQA/OKQ0ZpKAFozR2pDQAtFIKdQAU7+GmU5TigBw6U4GoyxpM0AS5oqME0oOaAH0CkBoFADhTqaKXNAAaKCaTNAC5oJpuaKAFzQDSGlFACiloFFADSKKU0UAdFaT3ECIUbcpG5Q1TzXkkwCsRjOeneqdvumaNUcKFGRnv7VpNCBHiQLubpigBtoN+7zBlCc4zzWnZRMF2qcAmsxR8wCAh+mR0q2kzxjJUkqeQKANxZGEgVdoB4LE1fjkhjh2Zb+9kdzXOK37pnIzGDnBPIrThZSqPn5Tx1oA14ZWIFsGVgBuBPQZqvu2M8bH5k4yKbAVkXETDch6noat22mveTSKjgkLkbaAMvVJ0jKsOVC5ya5HUb1YpTtfA5dVrqNbsiI5RvPy8Yrg9QtF81wXyc/Kx/lQBp22vRRKrHdI23OM8ZratPE6vGu1MHgNiuCmtGicqmPXIPenWt21jMpCg9eTQB6HKsVzNGwB3E5GK53V9OMWAynLMccdRWv4c1i2eNBcSLu9B1PtWpe2YuQwRiWYEJ7CgDz3ULE7FdUC8YIrGljKmvQ7mwAUP0KDa6muZ1KwMb9AVY5GO3pQBz9FWrm1eFiCOlViMUAJQKKBQAtFFFAB2opDRQA4UuabRQAtLmm0tAC0tNzRmgBe9OU4plLmgBSeTSq3TNMooAnzSZqMHnrUlABS0lGaAFoFNzS0AOooooAWlpKBQAhooNFAG5HDFFtWRwrEZGPX0qws5VgHPy4wPWsNNyODJl9xyDV1XJTC5aTOTu7UAbixhj5kT5U9vQ05QY+XbDe9VLckFWGQAPnGetaMcizN84BB6HHQUAEXOctk+tWofMG47lYdMDtTPs2NzHlR93Hc0/JV/mxnHVewoAvB2KDPy9ASvStfS9TlsZfPWPfGBjeveufjuVyB27ehq9HKgGwZAPTB4oAuXUr3k0jyAfvCScds1574ntJbWbDsADkV3hPJWM5bGM+tZviOwF9p5ZVUyxjcc9aAODsHEieSOT2z61Nf6VvUSR/IygbgfWqVlIsOo5k+VR8uPeuxmt1uUTy2yuAsg9R2NAHCIZrSTf0Kng13fhvxCtzB5NxII5RgA96yr3TMTPHIoDKdwGOCK5+a3aCQyQE5Q9PSgD1We3S54Vskr+dZdxpsaglQcN6+tVPBGuxzu8F7KEMcRZWbu1bbBJZAzEndyMdKAOW1e2Vow+3JHy7gOtc9fac0Q3pyprvp4wZlEWEQDoeeay7+1GzeDwzZIHrQBwbKVPIpproptPBYLIAC7YVhyDWfe6XJBIy919ORQBmZpac8TIeRTaAFpKKKACiiigBRS0gpaAEoopaADNFJQKAFpKWigAp4amUUAP3Ucmm08EAUAAyMU4VGTmnbqAH0tNBpaAFzSimZpwoAXGaKUUUAaKhCBtDFh1AqeEtk54dj+VPt1UbSFIBGD71YMZU7gMUASQo33tpA9PWrSr8vy9+hHYU1JVIXbzgcirSY48voeCKAJ4CRjD7gegPc1Z2gMS4XJ6AVXgEaKVIIYGrQjVj8rAjqKAKsilQOBjPp0qRCyuvlr8o5+tSMjmMhiCBx702PMUihh+7Pf3oAnimWNQ0gIGegq7DNuyrqpQ9PpWW0qlgAOD/ADqxFIAAcfd7rQBw/jTS5LK/do1PlyncpHStDwrf74R5gDeWQrj29a6zVrKLVtHlgwRcKNyH1FeXRGXStSxJuXna6juKAPQNYVZJVzlJB8y5HUVz19b8mRSDu64rZuZGu2hRmDFEG1h3FVGdV/dsu7PG4UAcndWb25MkRPB5+la2k6zKSsUjsqoOVJqe5tyV2sAQeOtYVzb+XIzqCWHagD0baJ40mRwcdhUEqENucBQDjmuP0nWpbNzGXxHnkda7Kwv7e+iG3BLLgkmgCm9okrYUBcEt7Gq3k78pInJ5DVpTWzKxAUjPAbtTkCbtvmHeDyaAObutOHQgZPpWVNprLnK9sjFdu1rukPmKMHgVXaxA4Cn5jwSKAOHNk2eKje1kU/drt7rTjBKuYvMTuU61A1mvmgY+Q+3NAHFGJx1WmlGHauxk01GkKlCuBnJHWqz6YMZ2gg9xQBy4U46UbT6V3vhrwauuWuv3Jufs1tpGmyX7OY93mMpASIDIwWJOD7Vhto7gldvzDtQBzuDRW0+mNj7tQvpsqdUIPuKAMvFFW5LZ16qarshHagBhNNzSmkxQA4UtJS0ALRmkNFADhzSgGkU4p6nNADVBBp9FM7daAH0q00AU8UAKaKQmigDYimLFfMXBI4x0qQyODgNkqcsarxBygJO3dwBU5iEi4PD45xQBft5D8hGMHk8VegKMcD+L9DWbB/qgGI29MCp4maPnHFAGvD9wgjLCpg+1Rjgtxj0qlFICVIJx0IBqfepUqR09aAJ5mKRhVZWyOTUVwVNtGrkmTOaa3AEioGVv4fSluWBVcjjHGaAGoNwOctJ/KpkPAAOwHtVSFxGwbJJHb1qyJ1dmAUA9TmgDUt5SCHEgG35Sfaub8eaSs9udTtFBQ4WXA6e9bFvNGcITxnHStOJY5I2spox5FwNoPvQB5foWoNkWkzkHP7tj/Kt9l8x5doxgcj3rnvFOjz6TqLowIKn5T7Vs2d8s8MVzGh3SL5bj3HegBLuJ8IAQcjrnkVTkh3bgwAbOMVpPbymYiNQ4Ubsmq86sSC6qB1570AYE9oyhlUgEGmWtxLZSho2YL0I961bxA75j7iqM0RCsW28DnPagDpbPxKsloYpCN4XBNakSxeVvL4yAfxrz4goFITAbr/jV621OeOT5pMoMDB70Aeh280TDMnzKeh71fsYvPKuAoXnBauSs9WjuIysgCEDjaelaem38kboF5jAwM/zoA6NbNVVgcN3BpF01QeEQqeDmnWl8JtrBl59atLcKQCRj39aAMuTSlk5APycc+lVb7SkbGAQA2QoFdQX3hQAPlGM+1MvLiK1hmmmGYY4zIxx2AzQBUt7V9L+FWphP+PnxBrMdqMf8+9ovmE/TzSVx71yk9pNCy71zKefavSvEFo1rJ4f0WXiXRtIRp1x/y9XTedOP0Q/8CrBu4l3eXg/P3oA4pI9pYzlMkY4HQ1KxhWCRniRnLAIWrcmskHyJGpkJ5JHaqN7ZgkBwPLyOg7+lAGTFpLXGVdEUOM7yOBisTVtI+zy7DjOAQRXoU7RPoXlRgC5ibJHqK5jUHE9zDI2FKALjvQBw1zaNGcjpVMjFdnqNmWLs23eeSAO1c5d2pUnAoAz6KVlKnBppoAWjNJS0AKKUGkFFADge1KBkU3NOU8GgB46UtJRQAGilooA24YwSM4yBnr0qVUZjtjYEdWIqvAoO2RRyeOtWdx3FgMHphaAJYzlehCnsOpqZWCsqsu4e9VxuVupG7ge1SpsI7nsB/WgCxG3z5QfITz7VdiePcFY5JqgqEqULAJ14o2tGBsIJznmgDQMvHyAkgkZ9KrzPJLJkr0HyrUQlZVYHg9TikjkeQYz2+U0APUkvlwcD07VYjIEuD0HP1qpDI4TgAnNPRzv+YHnt3oA1IiQC2BsPQd6t2t6I2VGJIX5l9jWdbSjoy/d71Mqg7sAYP60AXfEdqniHTcOAbyJcr/tCvOLK6bS75reXd5JPIx90131vK8MqsrZ29B7VzvjPT1a5E8Sny5BngfdNAHQaOrXUbRkxkMMDsSKr6jp01swGInhHY9aw/CV+8CqHBfaxBOeRXdEQ6lZHKjeRkNnmgDg/srNdmYEmFjyAOlNn08lncLvUDkiuvisfJWTCbZFHIPIIqK0slEjyHhW7dqAOIeDfESvJXjafSqs9rLECRGWXrXYXUMH2lkeLGfukDg1BbWyq24tlCfyoA4vEtqVK5x19xWrpmuGK4UTZKbu1dDe6ZBd/6kKWI4PTms7/AIRu4lUlNsboPTqaAOosr21aMSW8uYic47irpvyi/JgkjAFedtpOsaUTL5LlT3FaNh4leD91fw4YdGxg0AehWF+srYL7SOx712Pg7wVrHjCNJLVLI6NFqMcF0zzkSmNfLeT5NuDlWKj5vwrzOPUrK6SMwtlj39K+if2Z7pU8E+IpriVUgh1ZyXc4VEFrbkknsOpoA808YC/i8Z6xNrVnd2N3f3k88KzRMBLEhEaFWxtbEYizg8ZFZ+CSGbOSOKveKvE7eLfFN3rMm5bV/wBzYo+Rst1J2nHZnJLnvyB/CKoCVdqsFJANAE3lrG4MoGCOSKzr0KsjFQrI3TFWgzNkKcknJqNAglyTgDgD39aAMoW8wBkUckHBPcVk3lqyys4xtK7hgfpXVSRSkhlwAOOKyr6EoMpISR1GP0oA5kSEzrKVB28EN3qo9lHdeYCwSXG5V9avXZcMyyJgE4wOv1qO3ZY5hMIvMk5VAegoA5W9sSpIxgisuWMqcGu1eMSyZnxycEisXULEjdwMigDAxS1JJGUJBFMxQAlKKSjNAC0qnFIKUUASDpS00EYp1ACjpRSdqKANmAAKJM4RBjHqameQbQOAnUkVDGmxM7htA/OniQEYRQSRnNAE8cv3SuW5xmpEYfMygcdT6VXhDLjcOCOBU2WJwuNp5NAEqSAA/wATZ7VKSCjF8t3yO1QIRwxGw+vrUiEvtCjj0oAQMQ+XOEPPSo4mf5mVSUDcVpGJnRQAqAdfekW2CrsOcqcjHegCpBJ5khQqUyc8d6n3suXCkjPWrUUCJIGI+YDK+9SR5ifLJy5ztPSgCmGeU7c8HuKvRnEZLKCBxx601FRpSRH5ZP5UeVKm8MDtx0oAlYv8pAHAzn0pl5J9o0+eJfvYyCfWmIzIuMEKeeaVAH+VeG7570AcJFcyWd5nacfdYeldlo+qrCVCuCijv3FUdc00zzebAo3dJFA/WuXDzWzgjOA2CCOlAHrUVz5sqyxSDn+Fu9ShbedssTEWPTsTXnmn66Aj5YrIPug10FnqJvY9rjjhlfPegDSnXE7LIAyxnjFVY0VS6ugG5twYCrVriRJFBPmhgc+tOnC7HXBA7nHIoAzYo2lumh3Dj7pHHNXwkolZZZCFyBgDmiWzERQKQ/8AFkda17Fm8vcyjae5HIoAvaIsAm8u9ZpRsIUEcc1ZvPCei30ZE0aNkfK46/SqkYC7XjJcEcGtq3IKhI1+U85P8LUAcBJ4BAuHbTrpzGW+7/drodI1+80r4da14MsmDX97q7SXrqeEtfs9uAv/AG0II/3Vcd66C4kkjjLPEYrhTgOg+Vh71mta7LyWW2t1+0XGJJXB4bChf5AUAc5Fqt9GNr28TEHknjp2qtqHi5/LK29pmRDhgvNbepsBbSRRQpvBw4kGD+FY+gadb2809xKxVXYFVPPNAG74eNxqlmXmQxOGxnGMU+8intZtkxAHQNjrW3pup29pLGmBMkrBSAPun3rR1qzhjADLvRmVlJ7H0oA5JZnC7cnA6mqd3MDMo28KPmHrXQeJ7BYIDfQ4VN21wK5a6kWWZSoIXAxjvQBm6nHCMSKH3P1B/hrNJAciMHy26E9a073c0isoIHIANZcisrFXBGT+VAD2gjeHarj1GfWqdxF+7O/LSD261egxluMn+VW44xk/LuI65oA4rULQ8kCsZ1KsQa7++s/kCgDHOCetcpqtk0DAkcMN1AGTRSkYNJQAClBoooAWiiloAep4oqM8UUAbyr+4Bxk4/OnxRmPCgADqc06IlI0yo9KfIQoLMCQOTmgCVRkEk4Xp9KFk2jjBXOPwrJa6eafCOY4yelK0zQKcksc4AoA2VQsRkjA9ami3k5BVMg49xWTZTl92SzNjNa1vKrDaFATHU0AWozhPlBLAY5NSRu4TaRknvUa/KQVGQfWlVygOSSwOfpQBNG5P304xjdVnzsqQyh1x1PaqsbleW+vtTlYFeRznIoAndkIAU8njHpTvNG3Y5IPr71AQwkzkfNxuFPMZB2DBHqaALCYKlPvE9M1HLD8uTjIOBjtUbOyr1w+e3epkkbI3gcj5hQAixnDDdiU8ZqtLY2jsRIitkYOB3q0XBIwQCB09qTO7n5QaAOb1Tw4uN1qTwM4NZFmbjTZv3qu0YPIFd1JuQ/K25v0pxsbbUEKTLsmIOGHegDIs9RWXbLE/zg/StqK/HkMZ4yVc9fQ1zlzoMtpJ5kX3VOGxU9rcSbCkpyAeAaAN+N4lkcu/3l+U1oae0jRhlfBJ4B6VzsN6zXAQJGQVztat62uVjQBVDKDjb6GgDpNOCSRGG4AKk/Ky8YNX7GB1gmgcL833TnnI6Gsm3LQ2P2gBXUHJTPNWLe6eVjKAUYHIX1FAGulxHJbjfJ5cpOGjbp9ajlEYKhVyc/Kyms26nbzVZ/LfcOM9h6VC90n2fMLsGB3qD/D6igCPW2V8K6q4J+93z6Vx8VpdtJMElQbCdqs3IrbvryeW7V1QK38I7MfWuf1vTrq31X7YCyROOVzzuoA6zwPJJGTHfKjsfmL9ea7a+mF3bncAVDdK5DQrV204TMnls4w2eoFW576W22BYpGUY+ZR/OgDQuL97VHglt1uIJRyh7D1rmbjTg9xmzfy2xkRnsKvN4le6bymtiJIzjcBwQKzZriU3/nDgoMjH8jQBnXUUi7ZHG0bsZPrVeeNWdXcfUjvVXxJrMsz/ACQiNY+D7tUWkagLorFMdpx1NAD9m2Tg89cGrwjZ8E4VDycetRlAZDu59DV5ELhVySAe1AED2Zn2yTyLHEvG3HJrnvEloXeSZV/ck4T2FdjbhpGKJyQeCwrK1fTme1mkkZ0RH5x3zQB5ddRlHIqCtXVowHOAB7Csk0ALmlpKUUALS0goFADguaKVTxRQBryXKJHhnyvUDuapG6lnbamStVo4nkJYHPHQ96vweVGFxGQcY/GgB8YwFOBntipooXZf3uDk5HrSpCT9wZap0LHBbhsYOOgoAdHGCgO8AHjjtVqLC7EY4OMVDnaApwQO1TqVIAH3h60AWYi2wrvB5705QTu569qgZmcYJAI5xUkSmRjyMEUAWQVCjc/zA4xShTkHAPcn0quyMCg4GKduYkMe5xxQBZiK7c4OB/OngsQ25Sc8g1XDZPAwfWnq7HgE5x1oAlO7Gf4xwTSIzfNk8dzTGY7AOh9KVSxX5lAycH2oAfKQGI3be3PcUCQglgw6UvBIDnlf1FG35sDHIz0oAkjctnAAHqaXLADJIPYioVweC1PwSgAbgHigCzJcNkk871AI9TVKeON8Hj3xUqsQ2xjnuDTQAQwIwDyQOtAFbyBGd23Pceop+n301tM7Om5ScD6VIWCMpTJ7EHtTm27yJBuQc4XtQBtRgXyA28r+duyATxWtHefZ7dUdvnJyGxw3qM1g6VJFbuZlcg5yFPpWuL1pzDGUVIk+7le9AFlmHlOZRmI8p65rKnvCoAi5kU7cEcYqzIWEm5VKqMkx9azZ3aWRQqEkLzxQBd0y0TUL0O5ZIycDHbHerstvHfai0ZYskKk5Pf0oacafpaCJR55A2E+9WnSPStNEl7IPtd30C9RQBmajrA0mzVrtmG5sLH3f6e1R2XiSXU5MToYIWcRhQOfxonsFnv8Az75TL5kYRWfpGPUe9U1tY9PuWXlmL7gSaAN9NLWJGj85grsXB7gVVuLhbaEQeVvHVmHU1LY6kt4rh18qdRtJY8MPUUstsm95g7sgXaTjqaAOTuraJZ2eUEiUZBPIFZc8eGVYWBKkYI71092BJHsZCka/xYzn2rGZIoxIFxvDcA/3aALsU0byBgu5eBj3rZso2ZMqdhB4NcxbNgsyhirHqO1dVpDbokyeO4NAF6ztZgd3y+W33geoNY+u2sy3SWzkhZAWVV53ehrrtNQyq0ZwXY4ANUvE8MVrrCoWDSww5Hc0AeKa9HslYYwRwa549a6TxA4d2kz95if1rmz1oABS0gpcUALSikpRQAZPainL06UUAWoCCUCnnqRV+MDyiAMsT371WtogdvmHBOAvvVxX2hkIyRxgUAPHLDZuyTzUgPJXGF6cetMi4yCcLjjNTxI2NxbDMeBQAIG4yQcdal3qT0wq0wbQOUbPqKlRNpDAAqRx70ASrlTyu4k9T6UrAllWMgEcii35zuOBj8akxgZjXpzmgALkADPzY6+lKCc4B+6KUNv5KjrxjvQVLgENwPXvQBIN7gDhQBz704FlPy9R+tMPDYBO7vTx0zg5zk0ASLJnkgMOje1IBkHd69PagZPUgA88UoKg4wfr3NAC7S2MEipgp2gFSwz1FMw+4jI9KcgK/LvII6igB21WKJjBHQmneXhiAeQPwNIWDEgtwR6UoYqeDkHtigBjg7CANveiNA4Ypy3bNOkA2Bi+CKgt5fLmBweaAHFHYls4I6+xqPJDZI9s9zV64aJsup/dn731qo08RLHnAHX2oAntMJKkhQyITyp/nXQ2d/a3cEiFtgVslT1GO4rkbeaQM0TE+U/CnuBU7KiqcElk4B9vSgDr9UuIre0EikKzJhG9aydAFxeJJM+PL3bSa5W8ubye4ig3Hyw4AZvuqK9DslTT9OEcLpIpHzLnv60AU7x4n1ELcSgRRJu2/Sop2k126sr+LI8ngRnoKqwYvtWCGIKrDkk9avm9Gi6hLEsDMu3dhRxigDsbOxjubaKVwszE/Mh7Vy3i2ztrWcurFU5//VVrStbiLTTQyeXCxBw3UHvWRr2preal9mixIjruJI45oAjtYluDFHIVVJBmMjr+NWYEvrh47eR/KhjJBP8AeNV3hZFX7NKkcigZDdePSq76i09kYAJHux/y1XoKALSwtbM4djLag8L1Le9ZN2lvNfPLsKblwAe1NuLyYRJb7x8nBI9akvIVkEREhdXAyfSgBiRr5YUFguecd63dNVd8UYOJCMg1hoCoEe4kHpW1ZxtI6D7p3AEjt70Adn4ftTNukcELyA/uKwPFlleJe6jcsyBVttofvzXUXM62elrDC4EgwTzXn3jLV5Bq9zbSOcMi+YF5AxQB5hr748uIKAEHXvWEetaWrSmSUsT1NZpoAUUtIKWgApRRilxxQA8cDiikHC5ooA2YE/djBBXqAfWpUgY4Vh8xOSwqCDcEAYEFhmraMFUFmJOOcUANYgqEOMipFBK5GSaaXQMCuNp4INSY2ohOSWPQdhQA9Vk28ZX6+lTIpwdjdBmo1zt2hiR3JqcfKgPT1oABt2rg4fufWpF3sSv8J6kU3I2qQoIJwDT1J2EHrngDvQA9MYyvIHFDAkdPpTo124LD5sU7AbAxz1oAjCgEBTkVYBAXBOD6U0Ak5wOTjNP8tgPvLnpQA9Aqg9M9c0mwM4+apY9jdU+p7Uq7V5X/AOuKAGADcSSMZ4zShV+Y9SeTTiu8biQV6UOBhQxG0dCOtACKdseHpJZcLx1PSmswYEo5A6VFI/zenHU0APLYAPGentUbhgBnnrTVkGCpA3Crs1hcm18+FTIoGSAOgoAbAg2MJD8hwDih4EmLrB8r7dq+hqKxm8/MJwjkHk96jLzWLF5YyYR3Hb3oAg0+OVLyOGRGIJ6ntite2aJp2DKHwxDY7ipbjUBcaUjxpGSeBKv3selZtgoifa+dp4yOozQBsT6Et2cWk/ljOdrDgGqt/pF/pURM0xZM5BU9a6jwzNbrMYpirA4B3dOK6K+tI54pkIVlK8Z6CgDhfDP2a6jja6k8tiCvXke9aqpHY2O6Z/OnO4LnkuD0NVb3w08kY+yDy32469RWbOs1tPbs8nmGBDlc9+1AEkMUsNrG8cI3SyY296asFubmVZJtsh5VR0OKqxalJb28907ky8hMdATVSHfNp8e/m5d/kYdh3oAnFxc3d0qRIHlUEZzgAV0FrpwjtFn3r93Dovc1ztohgYqQ2WGFK9a0m8y2i+dHVV6qD3oAZdwRKzPBCqAjo3OTVGJi6FSdo3YCds0txdmdGGCpUd6dYx+YmGUr1waALVkgIJYbjnrW3pyPGyyScRAHLCsuzj8pWGCWxwa3DcW7aYbQOPMkQr6YoA0tWltLrw7NcLxcookDZ5dB1xXlfiR9gN3l910mVye2a6Wa6WGezj3M1vHGUbd0xXA+J75pZirEhU+VB6CgDnrp9z1XpznJzTaAFFKKQClxQBIoyDRjjFIDg0+gCM5AoqTFFAGrG2APMc4UcCpFLb/kwwP6VWjYNHlh8oAxipoiCU2HBySfegC1nb8uFbPU+lPUgo5Zs8fKBUEi78EABz1GalhjdYwCoGMgmgCxGQ/3Rn/Zqwp2jntxg1ShVgdqnBAxVlAVQ5y2OeaAJUK5DZyT0GKsRgkncQrjp71FEh4BIz7VOEXcARls80AKcKxJOeOBTlA9aHTL7l5zziliTMnJwe4oAcF3E5B56DtQARtLYCdzUmyQZBGA3f8Au0KiuuWzxx9aADzAoO05zziiQ85X25FIYTkHbmpYog7HbkAjBBoAQbU+bGeMn3qKRTkn1PAq0IvMRkTgNxzSCDORjheOaAKJVui557elVXUk7STkdPetdrNwMxsMHuaZ9lCH7u5vWgDGCESZKnYTtLV6H4YvI7ZDb3TLuVfkY9GHpXKm0XqO/Ue9aXkmSKFiMmMZBB9KAK3i7TFtb5bu0ZdjHcQD0PpTbZo723DqylcfOp7U3Un+0Sv8x+fqtZ9ohtZS6Ec9V7YoAimge0mIUkwnJyOlSW0bSMrbsnOQK6jw5BZ6g7x7+HGHiYdPcVJq/hFrBDcaYxePrsPUfSgDCsHlS7/ecbW3Y7mu0hnkKxrDNlWG4g9j6VzcMaTxMHGZEGG7EGrlsTGoWFnO0AHHrQBc1WHU5ZcQSFZCOx4ArldRsNQjDNI/z57d66hNSvLeaXzV3KMYJFVNY1GScMGhVAvP40AZVjADH5MxU5556ZrZ0rRvOuB9nwcKzYY8AetZMiBoU+TkHcxzU1vqM9kjLDJjehTnqBQA2J47aQO2GCtyfWnvfrcM+z5yx3LuqkImxh3+UEHJ9KeCpYJDgehIoAQgsQPlHPpVi2EomA2Mv95gO1ESL5oAOGY8E1rIwhg3M2WII4HU0ASRyw2aKT8wYYC9+azNYUf2pGVP7wrgD0PvU0+qW894kaQnfbxBgpH3z6/hWE8wM91fzSs1u6lEK9SxHagCnq160kbPuG1MRYFcNqM5lmJya2daukwqQk42jd7mudkbcTQBGaWkpRQA4UtAooAKlHQVGvUVJQAp6UUCigC2iFkwpx/WtG3gckbtuE5FRwxhRk9x09DV2OEuoIGWxk4PSgBoiXoBwTzUqxkIR3znmnAb0XpuA6VZgQbz/EMYz6GgBixEkPnIz0qeO2+YDIAzkZp8argYGT3NTqu9Sv3XzxnvQBH5RDH5wSO4qaNRtKqpIPJNPEBjIYNlh2qVAxOegznb60AR+WSRt49vQVKF5JKkY7mpDGWfB4J/SpkXd6kA4OaAK4JIG44BqQKDt28+gNSsvzHIBGeMCnxxYUkg8GgCLY2PmI4PSnyR5IIU4xnHpUpRhnCgZ45pUVgWLbs98UAQhTuwwG1TnPrUphwoYH73X2pyR/McA9c8+lOTndk/KRn6UARqnIyvQ0/y1yc9RUqjJUA5xwCacPmPI6dfegCAwhVLYGccVJAAI/lBGeoNSkKu0kblb9DTljzlhwffvQBXkt067A3PPrSLZwSLyvDcZx3q4gY8ngdDSeWTyrfUUAUzpUtjcCe2c/LzkfyrpLHV3uLUw3ZCSJ0b2rNWaS3YA8xfnUlxDDLF5sZCt1oAzdUjMc3mquSx6oP50+w1GG0SUEAbucnsas2l0HjdJBlEGV46muZ1VlvWPITrk+lAGxc6kLjCtKrY5/3qy2vo3YqwZ4wec+9ZP9mzLh1nDZGMZ6CrX9lSJEJBNuJHIB4FAFy8uAkKJGc5OT71FbTbH3SpyASMinlRHaKpXcxH5VFEDIFBO0k4x64oAtRJK7AlskkEDsBV61gNxeC3iTc3OD71BC0iyD5N0a9cda09N4lElq/lzIdy56kj2oAIoFEpeRDvRtpQjkUqyto9xf3QjWa1hjyVkP3C3cV3fijw5d3mn2muWtpsiubcCbHBRx3xXmmtaeGeDRZpHhMw8+Sdm++B2oAz55Y7zVJPsVyNjW4AlIxjPUVz+pXIiiNsVaNIRtQDufU1e1C6tuAVEbqDHuUcADoa4/UrtpHOWJPvQBWu5jI5qqaUnJpKAClFJS0AKKXHFIKenegBFHOafSUtAC5opMUUAb6FxGqBNoYDBqZBuhwVZSepBqNFJCHPOMjNWoEcAqwx/EcUASpGgQFj83b6VYjUbcJnnqfSo48NyvKdz3qxCG27uSCcAe9AE8SBRkjnsBTol3EsT7H1FCrjaTnnr9an8tsZUbSaAFTIB65PQ1OqkEEffHO6lT5UxzgcDipkVcZyc+vpQA2KMtkFuMU9UC9M7RyBTwAR827cfTvThCd3AO3OTQAAHdnbgdPrTjHmTcAcD1qRQ33iS2Oi1Iu4qec57elAEBDK4zhgePYVIqkclgFHU1IFUYU4Geopdqk4jwQemaAGKgXjqpHWlaNQwJTIPQA04D5sDoDUhIBO0dO9ADAAA+V9uKcgIbacc/nUi4XGT05JFLtCgdznIPegBqpg9BikeMjkkDHQU4Bcn72e4qQIpQc5I9aAExlTt4fvT+GUBgA2c8UBkGOct1wPSo5mjKKu4A4yCO9ACSyxgHOSvQr71Qe1lmk/0djgjO0mo572CNmDkmU/dx0NFzeiz00OPlnkUgKeoHrQB0Pg+90y1uTaX0qS+a4UcdD6VgeJdK/s/Xr6COPELNuUt71hW058+GVVAkVgUI7H1r2W3+y/EHwwzxQCPVrVSTjq2BQB4sumvv8AMDMp7irfkIpETs4XGRg9DUrMwnkSdXikU4ZMYwRTJIy0hbPyn1oAcMkHnjP41LFFmTcGAwMKT3qW0tXuZgscMkue6Ct+z8NxpIZNbP2eyXpGD88h9BQBT0axutYuTZ6fDl8gPJ2X1JNdFe3umeFZ7e1tbZb7UipE1033V9l9TSXHiOx8htO0Yrp9ui7WwP3jn3NcPew3E7xTMQ+xiYmU5VcdzQBY1LxHqd1HcWrareiUSfvbY8Ls9qwHuGttRa5uZWvgEO1GP3FxUmpSoltcPc3DPezEMTjBIrkNV1AucLgEDHFAEeo3hyVU1kMxJyetI7FmJJpKACiiigApaMUooABT16UgX1p2BmgBaKUClxQAlFIxwKKAOmi2rzjI296njkDODnjGMd8VDbqoXn5gBzntVmKNWYMOuc8elAFhd2VUABOvFWYjhtyZb0HbNRRR5G1W+bOauIoVdvQDnIoAkjIc7ZEI5zxVmKPIZmB+XgGmohbleeOlXY4wyfu14GOCelADEUnDBuOgqdI8AheMnk04RsCFwAo6ipwm7HGAOooAhQbsDOO1SIhBJ3H/ABFTiPpjbkHj2p/kNIONo96AK6ZQk5PPelCMHLAHLdT2qzsIGUPTA5p4G1ssflB5HrQBWEYAOeg6E+tG3K/Km0jrVkbTuA6HkZqMqRt2euMntQAxQchsg9vqKVUDHbgA+uaTauch+3TNVJiMEF+nU5oAtNwTg7QOpPeoZZeSzcEnqKz5bhNgQsck561VuZwOPMOevJ60AaT3L7SVlGM9O9Z91fSgyAEp7+9Zkt6RkqRVL7U0mSSwA6k0AbKXM8vzRzYfHUVSkuJ9wBuNhxg1Jpyb5kfcojT72T1FQ3NrIvQB4+SGXnjNAFzTAoadypkCJwW9T6VUJklnzcHe2NuDWjoaCWSIOQoMyjae696g1KPZfXCxr+78wgHuOaAK+M7jHkYPSt3wlr154Z12LUbKQsyrsmjPRlrIiRt42Ido7nvVpLYNkOfvDGBQB3mq+OdG1ZnF7oqrOxGXQdazrzUNDlKm209soP4j1rlltxEcbd0gPrSPOLeEl0LBjtAB5BoA3rnxFcRzGK2WOCIYJ8teRWVrupmcQXMd4/nbwoRzkjPeqX22O48y6J2Rr8nTkkCqdzg2dku0s8rjeSPm60AWpo4zqJiidvNSNnuJT0xiqraw1vpscEbBUVCGH97JqpqmprBNfBSVL/uyPUA965TUdQe4kJ4UYAwvTpQBZ1XVXnfJOcAKPoKxncscmmsSetJQAUCilFACUooApcUAApaMH0owaAHqc06o169aeKAHClptO7UAMYZBopTRQB1EeXCFgFwACB3q3EhJ3Y5B+XFUogDGpUkZHT3q7AGjADyBt3GB60AXVZXJK4WU8Y9quQMF2oMHNUomAcnA44z1xV2JvL6sCe9AF2JGUAg/P2AqykbR7dwIz19qgil2jBwQRww7VainO0BxuzznNAFhEYgfLvqZVyWLLtGOneohcYaM4x64pyXiGRtzK3GPxoAsEgZIQZ9PUUwlSMH5dw49hVKXVYC5ywRl/OqsmpRKMsw2+/egDXLMmw5DAdfSn+eAAGUc1z82ssvy7QF7L3IrMuNdwcE7epGO1AHYy3EKBSoLZ6VSlvLeIbjJgknK5rjJNfeQMVDbumR6VQl1RpoxwenJzzQB1N/qyLIRuO1fSsqbUjM7CNiCBkDNZAlkc7XOe/IpYQobIB69aALJupXIOABk555pnmSuoQEkAjk+lL5Q3qMYB607d823HOccelADmx5mAuFzjdRJGGB+Y7e6ikTONqEBW657VPEFc4LZkBx7EUAMJXhAOAOT/jVm2meIYjfAIBPpUKjYxVhgse1OQR/ef7pHFAF6WTzERwcFc4K+tRRu4Xc2Wbrk06K6jihaNk+XO8n0qFpQBiNsZHfvmgC0J9rLljg9fQGkM4WVmViWA+Ug1nyyDa8ALMR1PZTTVhV5MPKwtrfBdh13elAF67upI42LhjK2NoXvnoK0llEu83SRw3NtFvjUHhn9D71lCWBhPdvMFSH/AFSHqz9qxrzU4jvLliSM9erHuf1oA3Jpham1a6KqJV8yRQMgbjzWDqusYuy1tI21G/dk9h2rGvtTluGyzk4GB9KoM5bqaAJbq5eZiWYkk5JJqtmlNJ3oAKKWigAopaWgBBSjrSgZFPAoAKKDRQAmOacBRilFABinUlHegBDRS0UAdJHKI4VKH73Jz1FIlzyZEXqeh7VRSYP97hs4BoMwVMHqOMjvQBrLeBRsJK57nvU0d6wYAtyOD7isOItKwD52jpmpkQwncmGcdMmgDfTUdkYCjHOeT2p63paJ5nlK+nPGKwioIBIPI656mpdhFoqMd2W+VT2oA0m1Z8KplwjjpnvUb6w7DY2M9QV7Vjywqu7oT6+lN+yboS3mHLDKigC1Jqck0xwMMvBY9DVabUN5yzHjgEd6pTWszvGFYLxnb2P1pogZwzAjKjovrQBdfUJ1O+XlR8oJ60LKJISyZVh1z3ptwIsqkgL7UHT+9UccTBQwO1gc8/yoAlbqpO4BhkkVJCEBTILKep9KeC7usIVVZf4uxqKSVYpmUrucccetAF0oVYkfMVoJGBggA8kVWjdyiJktIT0HYU4FR06560AWDNlsHg9VHrTRkYU5HORg96hZlVyeC3TNOinSPLlxvHRSOtAF/ZM1qSY0LkfMAelRxOxAGBlew71WN2jylifLB5+UdKV9QDOjNsG09hQBYknYoQQVON2ByfpUhlJVWkRVOOBmqH21EIaI4YfxHkmq73YA3bsnnORQBriYvJhTlj0HrTM3AFzKjxtITtx2QDvWFJqW2QNFlCB1B9uTVf8AtKUIyqcBuo9aAOouLuGDyoBKrw5DSOOpPesu91aNZZVg/wBSX3BT3+tYMlw79zUBagC9NfO3SqckjOck0yigBc0UCigANApcUlABS0UtACUUuCacF4OaABOlPFNAwKdQAUgpaU0AFFApcUALSGig0ALnFFIaKALEcoeAttI3DH096kSQFVTaQSeDUCM6siAgZ7VYjLSGQlgpU96AJ1Qs22M7xnBbPSrNukZkyPur1561CkSyKyqzRJ2P941o2unRRWMU3nA7jgp60AOt40Y/ucso7elWBH5aLHJ+8ZuiAc06yjeWVoLeVIk67/Sp7aI216gs2NxchSxbqB70ARR2MallZCHPQP2NQS2KxziSRgrkdM8fStK0tLm5v3MFwrM0fmSvJ0X2FV7mGO2hUsxkvJGypPIx7UAUri03qcgxoq7iT3qKOKJYBJGNsK8M+Pve1Wta89YIIZJk3sMtzjFUNS2osSfallBXJWI8J/8AXoAVLSOQuVYKkXzMQeSaesO4KUizGnLM56mslZ1iQqv3c5Oe9RvesFKqxAPbtQBqXSQLbk5Ku5yAKzw6qcg5c9SaoPcs3BYnFQmY54NAG1/aBSJgP9axyznkkelU5bz3rOaQnvTCeaANBdQdHDRkhhnkVH9pPrVPNKTQBaa5b1qMzMe9QZpaAJDK3rSGRj1NMpBQA4mkzRRQAUYoooAKWilFACUoHNKBzTgvNACDhuaQ4zxTjnJNN6mgBQM0u2hRjNOFABilopaAExS0UUAKKKKKAFxRilFFACEUhpxppoAQ0UhPFFAEiSKiHeAzdjST3XmBABtVew71ULE0maAL738khRXYmNOg6VIdScoFJJGMVmiigDUj1MqmzbhD1UHrU1vrU1vGVhOzPGQeaxaM0AbB1m4C4DkcY4PUVA+q3DYJckjofSs4mkoAuyX0shLO5Zj1JOSaia4cjrVeigCUyE9TTSxNNooACaSlIpMUAGKMU4UYoAaaKWkxQAUopcUUAGKSnYooASilooAbRTiKMUAIKUDmnKvrThxQAAYp1JRQAdaQKKUU4CgBuKXFLQKAAUUtGKAGmjFOxS4oAbS0uKWgBKKD1ooADSUpooAY1FK3Q0UAVBSilHSigAoooAoAKKXFJQAh60UtJ3oAMUuKMUtACUtFFAAaTFLRQAUGilxQA3FLS4ooASlApcGnYIWgBpGKKc3ShelACEc4pwAopRQApFBFFFAB2pO1LRQAmKUCnUtADMUCnUmKAClFKKKACjFLRigBKUUmOaUdaACilxSUAFIaKKAEpRRQKABhxRSnpRQBTBooooAM04GiigBCabmiigAzQKKKAHZpCaKKAEBp2aKKAEzS5oooAM0oNFFABmnLg0UUAKThaaWzRRQA8HI5pR0oooAbn5sUueSKKKAFzzRmiigBQaXNFFAATS5oooAXNFFFABmgGiigB2aKKKACkzRRQAmaUGiigBCeaTNFFACinYxRRQAxzgUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The MRI pictured here shows increased signal in the distal clavicle (arrow) indicating the presence of bone marrow edema. This finding is consistent with osteolysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_7_24703=[""].join("\n");
var outline_f24_7_24703=null;
